

Review

Rho GTPase and Rho Kinase Signaling in Tissue Contractility and Intraocular Pressure Regulation

Srimathi Raghavan¹, Padmanabhan P Pattabiraman^{1,2,*} 

¹Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, IN 46202-5209, USA

²Stark Neuroscience Research Institute, Indiana University School of Medicine, Indianapolis, IN 46202-5209, USA

*Correspondence: ppattabi@iu.edu (Padmanabhan P Pattabiraman)

Academic Editor: Dario Rusciano

Submitted: 7 July 2025 Revised: 15 August 2025 Accepted: 21 August 2025 Published: 20 January 2026

Abstract

The Rho GTPase and Rho kinase (ROCK) signaling pathway is essential for cellular mechanics, acting as key regulators of the actin cytoskeleton and actomyosin contractility in various cell types and tissues. Rho GTPases, functioning as molecular switches, and ROCKs, their primary downstream effectors, influence vital cellular processes such as cell shape, movement, growth, and gene regulation. This review explores how this pathway maintains tissue tone, especially its significant role in regulating trabecular meshwork (TM) contractility. It also highlights the critical part of the Rho-ROCK pathway in precisely managing intraocular pressure (IOP). Dysregulation of Rho/ROCK signaling is a known factor in increased aqueous humor (AH) outflow resistance, a major cause of glaucoma, which is a leading cause of irreversible blindness worldwide. The review discusses the molecular mechanisms behind these processes, illustrating how the pathway affects the contractile behavior of tissues in the AH outflow pathway—including the TM and Schlemm's canal (SC)—by directly impacting actomyosin dynamics and extracellular matrix (ECM) remodeling. It also examines the extensive interaction between Rho/ROCK and other vital signaling pathways such as MAPK/ERK and serum response factor (SRF), emphasizing its integrated role within the complex cellular signaling systems in the AH drainage pathway. This comprehensive discussion concludes by highlighting the promising therapeutic potential of Rho kinase inhibitors (RKIs) as a new class of drugs for glaucoma. These agents not only effectively lower IOP but also show emerging neuroprotective properties, with broader implications for other eye and systemic diseases. Understanding this pathway—from its molecular structure to clinical applications—provides a strong foundation for future research and the development of more precise interventions.

Keywords: rho GTP-binding proteins; rho-associated kinases; actin cytoskeleton; extracellular matrix; trabecular meshwork; glaucoma; intraocular pressure

1. Introduction: The Ubiquitous Role of Rho GTPases and Rho Kinases in Cellular Dynamics

The Rho family of proteins constitutes a critical class of small guanosine triphosphate (GTP)-binding proteins, approximately 20–25 kilodaltons (kDa) in size, that are integral members of the broader Ras superfamily [1,2]. Often referred to as “GTP enzymes” due to their inherent GTPase activity, these proteins function as molecular switches [3]. Their regulatory capacity stems from their dynamic cycling between an active, GTP-bound state, typically localized at the plasma membrane, and an inactive, GDP-bound state, predominantly residing in the cytoplasm. This conformational shift upon GTP binding enables them to interact with and activate a diverse array of downstream effector molecules [4,5].

These Rho proteins include about 20 members, as shown in Table 1 (Ref. [6–23]). Among them, RhoA, Rac1, and Cdc42 are the most studied, each affecting the actin cytoskeleton [2,24–26]. RhoA primarily promotes the assembly of actin stress fibers and focal adhesions, which are crucial for cell adhesion and tension generation [27]. In con-

trast, Rac1 controls the formation of lamellipodia and membrane ruffles, which are essential for cell migration [28,29]. Cdc42 mainly governs the formation of actin microspikes and filopodia, structures important for cell sensing and exploration [30–32].

Beyond their well-documented roles in cytoskeletal reorganization, Rho GTPases are essential to various fundamental cellular processes. These include establishing and maintaining cell polarity, regulating cell adhesion, orchestrating cell motility and migration, facilitating vesicle transport, developing and maintaining synaptic structures, supporting wound healing, and executing cytokinesis [33–39]. Their widespread involvement emphasizes their critical role in maintaining cellular integrity and function across diverse biological contexts.

Rho-associated protein kinases (ROCKs), specifically ROCK1 and ROCK2, are the best-known and most studied downstream effectors of the small GTP-binding protein Rho, especially RhoA [40]. The ROCKs are serine/threonine kinases with a molecular mass of about 160 kDa, and they play a crucial role in mediating RhoA-induced reorganization of the actin cytoskeleton [40]. The



Copyright: © 2026 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.

Publisher's Note: IMR Press stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Table 1. List of Rho GTPase and their functional role in cellular level.

Rho GTPase family	Rho GTPases subfamilies		Functions	Reference
1	RhoA		Actin myosin contraction, stress and fiber formation	[6]
2	Rho subfamily	RhoB	Cell adhesion and migration	[7]
3		RhoC	Migration and invasion	[8]
4	RhoH subfamily	RhoH	TCR activation	[9]
5		Rac1	JNK activation, actin filament stabilization, PIP3 level	[10]
6	Rac subfamily	Rac1B	Cellular transformation	[11]
7		Rac2	B cell adhesion	[12]
8		Rac3	Regulation of cell adhesion and differentiation	[13]
9	RhoG		Microtubule dependent transport	[14]
10	Cdc42 subfamily	Cdc42	Actin organization	[15]
11		RhoQ (TC10)	Actin organization, vesicular trafficking	[16]
12	RhoJ (TCL)		Stabilization of focal adhesion	[17]
13	RhoD/F subfamily	RhoD	Growth cone formation	[18]
14		RhoF (Rif)	Actin organization	[18]
15	RhoU/V subfamily	RhoU (Wrch)	Cell shape and cell adhesion	[19]
16		RhoV (Chp)	Cell shape and cell adhesion	[19]
17		Rnd1	Microtubule depolymerization	[20]
18	Rnd subfamily	Rnd2	Neurite branching	[21]
19		Rnd3 (RhoE)	Loss of stress fibers	[22]
20		RhoBTB1	Not well characterized but like RhoBTB2	[23]
21	Rho BTB subfamily	RhoBTB2	Tumor suppressor	[23]
22		RhoBTB3	Vesicle trafficking, tumor suppressor	[23]

functions of ROCKs are diverse, affecting many cellular processes such as contraction, motility, proliferation, apoptosis, cell shape, secretion, and gene expression [41–44]. The RhoA/ROCK pathway is one of the two main pathways controlling smooth muscle contraction, working alongside myosin light chain kinase activated by calmodulin. They work together by affecting the phosphorylation state of the myosin light chain (MLC) [45,46]. It is a key regulator of actomyosin contractility, which is essential for force generation in processes like cell movement and muscle contraction.

Rho GTPase and ROCK signaling are crucial and found throughout various biological systems. By establishing their role as fundamental regulators of cellular mechanics, particularly actomyosin contractility, we will provide details on their role in the mechanism of tissue contractility, the regulation of intraocular pressure (IOP), and the implications for ocular diseases, notably glaucoma.

2. Key Rho GTPase Members and ROCK Isoforms

RhoA, Rac1, and Cdc42 are the most thoroughly studied members of the Rho GTPase family, each playing unique yet interconnected roles in organizing the actin cytoskeleton and related cellular processes [47]. Their specific functions are summarized in Table 2.

ROCK1 and ROCK2, the two isoforms of Rho kinase, share significant structural homology, with about 65% overall amino acid identity [48]. However, they differ in

their cellular localization and activation mechanisms. For example, ROCK1 is mainly found in the cytosol, while ROCK2 can be located in both the cytoplasm and nucleus, often co-localizing with actin and vimentin filaments [43]. Despite their structural similarities and often shared downstream substrates, ROCK1 and ROCK2 do not fully compensate for each other's loss. This indicates they have distinct or non-redundant functions in certain developmental or disease contexts, such as the known role of ROCK2 in blastocyst development [49,50]. Their different expression patterns and activation processes contribute to the complex regulation of cellular functions [48].

3. Molecular Architecture and Regulation of Rho GTPase and Rho Kinase Signaling

The structure and regulation of Rho GTPases and Rho kinases enable them to control cellular processes precisely. Understanding these structural and functional details is essential for appreciating their roles as molecular switches and effectors.

3.1 Structural Domains of Rho GTPases

Rho GTPases are monomeric proteins (~20 kDa) characterized by a conserved core G domain [51–53]. This G domain is a defining feature of the Ras-like GTPase superfamily and contains five conserved sequence motifs (G1–G5) that are essential for binding and hydrolysis of guanine nucleotides. The G1 motif, or the P-loop, is crucial because it coordinates the β -phosphate of the bound nucleotide and

Table 2. Major Rho GTPase family members, their main cellular functions, and key effectors.

Rho GTPase member	Primary cellular functions	Major effectors
RhoA	Formation of actin stress fibers and focal adhesions, actomyosin contractility, cell motility, cell proliferation, apoptosis, regulation of vascular tone, glucose uptake (via GLUT4 translocation)	Rho-associated protein kinases (ROCK1, ROCK2), mDia (formin family)
Rac1	Formation of lamellipodia and membrane ruffles, cell migration, cell polarity, synaptic development and maintenance, force-dependent growth of adherens junctions	WAVE, Arp2/3 complex
Cdc42	Formation of actin microspikes and filopodia, cell polarity, synaptic development and maintenance, cytokinesis, cell migration	N-WASP, Arp2/3 complex

the Mg^{2+} ion, both of which are necessary for nucleotide binding. RhoA, RhoB, and RhoC share identical sequences in this critical region [53,54]. Experimental modifications of this motif, such as the Gly14Val mutation in RhoA/B/C, can make the protein constitutively active, effectively in a “GTP-locked” state [52,55,56]. Conversely, the Thr19Asn mutation in these isoforms results in low nucleotide affinity, leading to a dominant-negative phenotype. These mutants are frequently used in biochemical and cell biological studies to identify specific interaction partners and explore the biological functions of these GTPases [52,57,58].

The isoforms RhoA, RhoB, and RhoC also share identical sequences in their switch I (residues 27–43 in RhoA) and switch II regions (residues 57–68), with only minor variations at positions 29 and 43 within switch I [52,59–61]. These subtle differences can significantly influence the binding affinity of RhoGEFs and downstream effectors. These switch regions undergo substantial conformational changes upon GTP binding, which is the molecular basis for the active Rho GTPase to engage with its downstream effectors. A highly conserved glutamine residue (Gln63 in RhoA/B/C) located within the switch II region is vital for coordinating the nucleophilic water molecule relative to the GTP γ -phosphate, thus facilitating both intrinsic and GAP-catalyzed GTP hydrolysis [62–64]. Mutations at this residue, such as to leucine or alanine, can make a Rho GTPase constitutively active by impairing GTP hydrolysis [65–67]. Additionally, the carboxy terminus of Rho GTPases typically features a common domain, including a cysteine residue, which undergoes essential post-translational modifications like prenylation [54,68,69]. This modification is crucial for their proper localization to the plasma membrane, a prerequisite for their active state.

3.2 Mechanisms of Activation and Inactivation

Three main classes of proteins orchestrate the dynamic regulation of Rho GTPase activity.

3.2.1 Guanine Nucleotide Exchange Factors (GEFs)

These proteins act as positive regulators, facilitating the activation of Rho GTPases by catalyzing the exchange of their bound GDP for GTP. The Dbl homology (DH) domain within GEFs is specifically responsible for this guanine nucleotide exchange activity [70,71].

3.2.2 GTPase-activating Proteins (GAPs)

Acting as negative regulators, GAPs speed up the natural GTPase activity of Rho GTPases, aiding in the breakdown of bound GTP into GDP. This results in the inactivation of the protein and the ending the signal transduction. GAPs have a conserved catalytic Rho GAP domain [72].

3.2.3 Guanine Nucleotide Dissociation Inhibitors (GDIs)

GDIs play a crucial role by inhibiting the dissociation of GDP from Rho GTPases, thereby stabilizing their inactive GDP-bound state and sequestering them in the cytoplasm [73,74]. They also regulate Rho GTPases by binding to their isoprenyl groups, facilitating their extraction from membranes and thus controlling their localization and activity [75,76].

Beyond these core regulatory proteins, post-translational modifications (PTMs) significantly increase the complexity of Rho GTPase signaling. While prenylation is essential for plasma membrane localization, other PTMs such as phosphorylation, ubiquitination, and palmitoylation affect the stability and spatial distribution of Rho GTPases [47,77,78]. For ROCKs, autophosphorylation of ROCK1 at Ser1333 and ROCK2 at Ser1366 indicates their activation status, and phosphorylation at other specific sites, including ROCK2 Thr967, can further enhance their activity [79,80].

Spatiotemporal precision is crucial for regulating Rho GTPase [81,82]. Carefully adjusting Rho GTPase activity across different cellular locations is vital for achieving specific biological effects. This dynamic spatiotemporal activation is often managed by GEF and GAP complexes that interact with various proteins, including components of the cytoskeleton, focal adhesion proteins, adaptors, and Rho GTPase effectors [83]. Such flexible control allows for the diverse and context-specific cellular responses observed, ensuring Rho GTPase activity matches cellular needs. Furthermore, Rho-independent activation mechanisms for ROCKs, like caspase cleavage, add an extra layer of complexity, signaling alternative pathways that could be targeted therapeutically or may contribute to disease independently of Rho GTPase activity. Understanding these mechanisms is essential for developing precise interventions.

3.3 Structural Domains of ROCKs

The ROCKs, ROCK1 and ROCK2, are serine/threonine kinases that belong to the AGC family of kinases [43,48,84,85]. Structurally, both ROCK1 and ROCK2 consist of an N-terminal kinase domain, a central coiled-coil domain containing the Rho-binding domain (RBD), and a C-terminal auto-inhibitory region [86]. Although their kinase domains are highly similar (92% amino acid identity), their coiled-coil domains are more different (52% homology), which may explain their distinct functional roles [48].

The C-terminal region of ROCKs functions as an auto-inhibitory domain by directly interacting with the kinase interface [87]. Removing this inhibitory part results in constant kinase activation both *in vitro* and *in vivo* [88,89]. The main way ROCK gets activated involves the binding of active GTP-bound Rho (such as RhoA) to the RBD [90]. This binding breaks the auto-inhibition, causing a shape change that leads to an active, “open” form of the kinase domain [86]. Besides Rho-GTP binding, ROCKs can also be activated through mechanisms that do not depend on Rho. ROCK1 can be activated by cleavage through caspase-3 [91], while ROCK2 can be activated by granzyme B and caspase-2 cleavage [92], both of which produce always-active kinase fragments.

4. Rho/ROCK Signaling in General Tissue Contractility

The Rho/ROCK signaling pathway is a key regulator of cell and tissue contractility, orchestrating the dynamic interaction of the actomyosin cytoskeleton across various cell types, as shown in Fig. 1. Its role spans from essential cellular processes to the overall function of tissues.

4.1 Detailed Mechanisms of Actomyosin Contractility

ROCKs are essential in promoting actomyosin contractile force generation, mainly by increasing the phosphorylation of the regulatory light chain of myosin II (MLC2) (Fig. 1). This occurs through a dual mechanism.

4.1.1 Inhibition of Myosin Light Chain Phosphatase (MLCP)

Activated ROCKs phosphorylate the PPP1R12A/MYPT1 subunit of myosin light chain phosphatase (MLCP). This phosphorylation inhibits MLCP activity, thereby reducing the dephosphorylation of MLC and leading to sustained, elevated MLC phosphorylation and prolonged contraction [93–95]. ROCKs can also phosphorylate CPI-17 (Protein Kinase C Potentiated Phosphoprotein Phosphatase 1 Inhibitor), which further contributes to MLCP inhibition and enhances Ca^{2+} sensitization of smooth muscle contraction [1,2,66,96–98].

4.1.2 Direct MLC Phosphorylation

In addition to inhibiting MLCP, ROCKs can directly phosphorylate MLC. This direct phosphorylation stimulates actomyosin ATPase activity, which is a key step in initiating contraction, and contributes to Ca^{2+} -sensitization of smooth muscle contraction and stress fiber formation [99–104].

Beyond direct myosin regulation, ROCKs also influence actin filament dynamics through the LIM Kinase (LIMK) and Cofilin pathway [105,106]. ROCKs phosphorylate and activate LIM kinases (LIMK1/2). In response, activated LIMK phosphorylates and inhibits the actin-severing protein cofilin. By preventing cofilin from severing actin filaments, this pathway promotes actin polymerization and increases the stability of actin filaments, thereby contributing to stress fiber formation. Additionally, active RhoA facilitates actin filament polymerization by binding to and activating mDia1, a member of the formin family of actin nucleating factors [107]. The combined effects of these mechanisms—MLC phosphorylation, MLCP inhibition, the LIMK/cofilin pathway, and mDia activation—lead to a substantial increase in the contractile force exerted by myosin II on actin filaments. This results in enhanced stress fiber formation, robust actin filament growth, and stabilization of the actin cytoskeleton. Collectively, these molecular events support the cell and tissue’s ability to generate mechanical force and maintain structural integrity [27,108].

The diverse array of direct and indirect targets of ROCK moving beyond just the core contractile machinery to include proteins involved in actin dynamics, intermediate filament organization, and even signaling proteins is shown in Table 3 (Ref. [46,103–105,107,109–125]). This comprehensive overview demonstrates the pleiotropic nature of ROCK signaling and how it orchestrates a wide range of cellular functions.

4.2 Role in Smooth Muscle Contraction

The Rho/ROCK pathway is a key, calcium-independent regulator of smooth muscle contraction, playing an important role in various systems. Its role in the cardiovascular system has been studied extensively [126,127]. It modulates MLC phosphorylation, thus contributing to agonist-induced Ca^{2+} -sensitization in smooth muscle contraction. This means that even at constant intracellular calcium levels, activating the Rho/ROCK pathway can enhance the contractile response. Excessive or prolonged activation of RhoA and/or ROCKs can cause hypercontraction. This pathological state leads to different vascular problems, including age-related hypertension, arterial stiffening, and vasospasm in coronary and cerebral arteries [127]. ROCK activity is also essential for maintaining myogenic tone, the inherent contractile activity of blood vessels, and the tonic component of vascular smooth




Fig. 1. Activation and functional role of RhoA in actin polymerization and actomyosin contraction. Created in BioRender™. GEF, Guanine Nucleotide Exchange Factor; GAP, GTPase-activating Protein; RBD, Rho-binding domain; LIMK, LIM Kinase; MLCP, Myosin Light Chain Phosphatase; MLC, Myosin Light Chain.

muscle cell contraction in various vascular beds, ensuring proper regulation of blood flow [128–130].

4.3 Role in Non-Muscle Cell Contractility

In non-muscle cells, ROCKs control a diverse range of cellular processes that are intimately dependent on actin cytoskeleton organization and cell contractility [126]. These include cell-matrix and cell-cell adhesion, cell migration, neurite retraction and outgrowth, and cytokinesis. Actomyosin contractility, driven by Rho/ROCK signaling, is a key determinant for various forms of cell migration and invasion, including cancer cell metastasis [131]. High levels of RhoA/RhoC or ROCK-driven actomyosin contractility can promote amoeboid motility, a rapid mode of cell movement. Rho/ROCK signaling also plays important roles in tissue morphogenesis during development, as evidenced by its influence on eye and wing development in *Drosophila* [132]. In the context of wound healing, Rho and Cdc42 are essential for the stabilization of the actomyosin ring, while

Rac is required for actin mobilization towards the wound site, highlighting the cooperative nature of Rho GTPases in this process [133]. Beyond contractility, Rho/ROCK signaling influences other fundamental cellular functions such as cell proliferation, differentiation, and apoptosis [134,135].

4.4 Mechanotransduction: How Mechanical Forces Influence Rho/ROCK Activation

Cells are constantly exposed to and respond to various mechanical forces, which can originate externally, including fluid shear stress on endothelial cells, compression on skeletal cells, or internally generated by the contractile actin cytoskeleton [136–138]. These mechanical forces trigger multiple signaling pathways, many of which converge to activate RhoA. The mechanical activation of Rac1 is required for the force-dependent growth of adherens junctions, demonstrating how physical stimuli can directly engage Rho GTPase activity [139,140].

Table 3. Major downstream effectors of Rho/ROCK signaling and their roles in actomyosin contractility.

Effector/Target	Role in actomyosin contractility/cellular function	Associated Rho GTPase/ROCK action	References
Myosin light chain (MLC)	Increases actomyosin contractility and stress fiber formation	Direct phosphorylation by ROCK; stimulates actomyosin ATPase activity	[104,109]
Myosin phosphatase target subunit 1 (MYPT1) of myosin light chain phosphatase (MLCP)	Sustains MLC phosphorylation, increases Ca^{2+} sensitization of smooth muscle contraction	Phosphorylated by ROCK, inhibiting MLCP activity	[103,110]
LIM kinases (LIMK1/2)	Leads to actin filament stabilization and polymerization; coordinates microtubule destabilization and actin formation	Phosphorylated and activated by ROCK; phosphorylates and inhibit cofilin	[105,111]
CPI-17	Enhances Ca^{2+} sensitization of smooth muscle contraction	Phosphorylated by ROCK; inhibits MLCP activity	[46,112]
mDia1	Promotes actin filament growth and polymerization	Activated by RhoA; nucleates actin polymerization	[107,113]
ERM proteins (Ezrin, Radixin, Moesin)	Regulates actin filament/membrane interaction; involved in microvilli formation	Phosphorylated by ROCK; decreases intra- or intermolecular head-to-tail association	[114]
Adducin	Involved in spectrin/F-actin network assembly; increases cell motility	Phosphorylated by ROCK; increases adducin/F-actin interaction	[115]
NHE1 ($\text{Na}^+ - \text{H}^+$ exchanger 1)	Promotes actin stress fiber formation	Stimulation of its $\text{Na}^+ - \text{H}^+$ exchanger activity by ROCK	[116,117]
Intermediate filaments (GFAP, NF-L, Desmin, Vimentin)	Involved in regulation of cytokinesis	Phosphorylated by ROCK; inhibition of filament formation	[118–121]
Tau, MAP2, CRMP-2	Involved in microtubule dynamics and growth cone collapse	Phosphorylated by ROCK; reduction of Tau activity, unknown effect on MAP2, CRMP-2	[122,123]
PTEN	Decreases intracellular $\text{PtdIns}(3,4,5)\text{P}_3$ level; tumor suppression	Stimulation of phosphatase activity by ROCK; promotes anti-survival	[124,125]

This highlights a crucial aspect of Rho/ROCK signaling, it acts not only as a responder to chemical stimuli but also as a sensor and transducer of physical forces. This pathway dynamically influences cell shape, adhesion, and contractile properties in direct response to the mechanical environment. This is not merely a passive response but a dynamic, bidirectional interplay where mechanical forces *activate* RhoA, and activated RhoA then *generates* intracellular tension [141]. This feedback loop is fundamental to understanding tissue homeostasis and disease, particularly in mechanically sensitive tissues like the trabecular meshwork (TM).

5. Rho/ROCK Signaling in Intraocular Pressure Regulation

The regulation of IOP is a finely tuned physiological process essential for maintaining ocular health [142]. Dysregulation of ocular pressure is the primary modifiable risk factor for glaucoma, a leading cause of irreversible blindness worldwide [143]. The Rho/ROCK signaling pathway plays an indispensable role in the delicate balance of AH drainage and IOP [144].

5.1 Aqueous Humor Dynamics and Glaucoma Pathophysiology

IOP is maintained by a precise equilibrium between the production of AH by the ciliary epithelium and its drainage from the eye [145–147]. The primary route for AH outflow, known as the conventional or TM outflow pathway (Fig. 2), accounts for most (up to 90%) of AH drainage. This pathway is anatomically complex, comprising the TM, the juxtaganular tissue (JCT), and the endothelial lining of Schlemm's canal (SC) [146–150].

In primary open-angle glaucoma (POAG), the most prevalent form of the disease, elevated IOP arises from a pathologically increased resistance to AH drainage through this conventional outflow pathway [151,152]. This sustained elevation in IOP exerts mechanical stress on the optic nerve head, leading to structural changes in the lamina cribrosa. These changes, in turn, impair retinal ganglion cells (RGCs) and their axons, ultimately resulting in progressive vision loss. The intricate interplay between cellular contractility, extracellular matrix (ECM) dynamics, and mechanotransduction within the outflow pathway is critical for understanding IOP homeostasis and the pathogenesis of glaucoma.




Fig. 2. Overview of a healthy aqueous humor flow pathway. The aqueous humor produced by the ciliary body flows between the lens and iris to enter the anterior chamber. From here, it drains through different layers of trabecular meshwork (TM), juxtaglomerular (JCT), and reaches Schlemm's canal (SC), thus maintaining the intraocular pressure (IOP) homeostasis. Created in BioRender™.

5.2 Specific Involvement in Trabecular Meshwork and Schlemm's Canal Contractility

The cells within the TM and SC exhibit characteristics akin to smooth muscle cells, including the expression of key contractile proteins like α -smooth muscle actin and myosin [153–155]. Their ability to contract and relax dynamically, together with cell-substratum and cell-cell adhesive forces, is considered crucial for maintaining normal AH outflow facility.

5.3 Cellular Mechanisms Influencing Cell Stiffness, Cell-Cell, and Cell-ECM Interactions

Activation of the Rho GTPase/Rho kinase signaling mechanism in the trabecular outflow pathway leads to an increase in IOP by altering the contractile, cell adhesive, and permeability barrier characteristics of the TM and SC tissues [156–158]. This pathway promotes myosin II activity primarily by inhibiting MLCP and directly phosphorylating MLC, which drives the assembly of contractile actomyosin bundles that generate strong tensile forces within the cells. This activation significantly increases cell stiffness through the formation of actin stress fibers [96,159,160].

Physiological agonists known to activate Rho/ROCK signaling, such as transforming growth factor- β 2 (TGF β 2), endothelin-1, thrombin, and lysophospholipids, consistently reduce AH outflow facility [154,156,161–165]. TGF- β 2, a profibrotic cytokine found at elevated levels in the AH of POAG patients, is particularly implicated in inducing CLANs formation via both SMAD and non-SMAD, including the Rho-ROCK pathway [166–170]. This mechanism directly contributes to increased cell stiffness and outflow resistance, mirroring the pathological changes observed in glaucoma. Activation of RhoA in TM cells by RhoAV14, TGF- β 2, or pressure leads to significantly increased levels of various ECM proteins, including fi-

bronectin, laminin, and tenascin C. It promotes their enhanced filamentous organization and assembly [158,164, 165,171,172]. This process involves mechanotransduction, where TM cells sense RhoA-induced contractile activity and cytoskeletal tension, which in turn stimulates ECM synthesis and assembly. The observation that RhoA-mediated induction of collagen, fibronectin, and α -SMA expression, a marker of contractile activity, suggests a feedback loop where ECM assembly can further promote contractile activity, potentially exacerbating the dysfunction. Erk activation, a downstream target of RhoA, is identified as a critical checkpoint under persistent RhoA activation, leading to both cytoskeletal contraction and increased ECM synthesis/assembly [165]. While Erk is crucial for both fibronectin and α -SMA expression, serum response factor (SRF) specifically regulates α -SMA expression, illustrating the nuanced regulatory mechanisms involved [165,173–175]. Thus, suggesting a transcriptional control of actin cytoskeleton-based contractility in the TM outflow pathway.

5.4 Impact of Rho/ROCK Pathway Activation Versus Inhibition on Aqueous Humor Outflow Facility

The consistent observation that activation and the inhibition of the Rho/ROCK pathway increase and decrease the outflow resistance, respectively, is the basis for providing Rho/ROCK as a prime therapeutic target to treat ocular hypertension and slow the progression of glaucoma.

5.4.1 Activation

Sustained activation of Rho GTPase/Rho kinase signaling in the AH outflow pathway consistently increases resistance to AH outflow. This leads to the stiffened and contractile morphology of TM cells, reducing the permeability of the outflow pathway [156,176–178]. Additionally, in-

creased Rho and activation of Rho have been documented in the optic nerve head (ONH) [179–181].

5.4.2 Inhibition

Conversely, inhibition of Rho kinase with specific inhibitors like Y-27632 effectively lowers IOP by inducing relaxation of the trabecular meshwork, thereby enhancing AH outflow [156,182–194]. The relaxation is achieved by reducing MLC phosphorylation and disorganizing the actomyosin cytoskeleton, leading to cellular relaxation and a decrease in cell-substratum adhesions in TM and SC cells. The result is an increase in the size of intercellular spaces within the TM, which directly facilitates increased aqueous outflow. Furthermore, ROCK inhibitors reduce the density of actin stress fibers in TM and SC cells, contributing to eased AH outflow [144,194,195]. ROCK inhibitors have also been shown to reverse TGF- β 2-induced cytoskeletal rearrangements (disassembling stress fibers and CLANs) and reduce fibronectin deposition, leading to a looser mesh and enlarged intercellular spaces in the TM [164,165,169,170,196,197]. This detailed mechanistic explanation reveals the intricate, multi-faceted interplay between actomyosin contractility, cellular stiffness, cell adhesion, and extracellular matrix (ECM) dynamics within the TM and SC. It is not merely about muscle contraction, but how Rho/ROCK-mediated cytoskeletal tension directly influences the physical properties and permeability of the outflow pathway tissues and their surrounding ECM [198]. Rho kinase inhibitors have also been shown to be neuro-protective, thus enhancing their role to treat glaucoma and slow the progression of vision loss in humans and animal models [199–202].

6. Crosstalk With Other Key Signaling Pathways

Rho GTPases operate within a highly complex molecular network characterized by extensive crosstalk, where individual members and their downstream pathways frequently cooperate or antagonize each other to fine-tune cellular responses [203]. Such an intricate molecular signaling cross-talk can manifest at multiple levels: through the regulation of Rho GTPase activity itself via shared or specific GEFs and GAPs, through the modulation of protein expression and stability, and the direct or indirect regulation of downstream signaling pathways [25,204]. Interestingly, the activation of RhoA and Rac1, two Rho family members, exhibits temporal or spatial separation [205], or one may actively inhibit the other, demonstrating a sophisticated balance in cellular control [160,206] as shown in Fig. 3 (Ref. [130]). This intricate integration of Rho/ROCK signaling with other major pathways is a crucial aspect of cellular regulation.

6.1 Interactions and Regulatory Loops With the Ras/MAPK/ERK Pathway

Both Ras and Rho proteins function as GTP-regulated molecular switches that govern multiple, often interconnected, signaling pathways in eukaryotic cells. The mitogen-activated protein kinase (MAPK) pathway, particularly the extracellular signal-regulated protein kinases 1 and 2 (ERK1/2), is a well-established regulator of cell growth, proliferation, differentiation, and motility. The Rho/ROCK and Ras/MAPK/ERK pathways intersect at numerous points, and their coordinated action is crucial for various cellular processes, including oncogenic transformation and in the TM [165,171,207].

Specific mechanisms of crosstalk include:

- Ras-dependent triggering of Rho activators, some of which operate through the PI3K pathway, represents a direct point of connection between Ras and Rho signaling [208,209].
- Mechanical feedback, driven by actomyosin action—a primary domain of Rho/ROCK activity—can influence the Ras/MAPK/ERK pathway, demonstrating how physical forces can integrate into these signaling networks [210,211].
- Direct action of Erk on RhoA can stimulate the formation of active GTP-loaded RhoA, indicating a regulatory loop where MAPK can influence Rho activity [212,213].
- Studies have demonstrated that Rho/ROCK and Ras-ERK pathways can function cooperatively to influence cellular motility and growth [211].
- In some cell types, such as glioblastoma, ROCK inhibition has been shown to cause a time-dependent suppression of p-ERK levels, and PDGF- or FN-induced p-ERK activation can be suppressed by ROCK inhibitors [214,215]. This suggests that ERK may function downstream of Rho/ROCK in these cells, indicating a hierarchical relationship in specific cellular contexts.
- The Rho/ROCK pathway also promotes the nuclear translocation of Myocardin-related transcription factor (MRTF-A) [216,217]. Once in the nucleus, MRTF-A interacts with serum response factor (SRF) to induce the transcription of target genes [218,219], including those vital for sensing tension, vascular integrity, and growth. This process is mediated by ROCK-induced actin polymerization via the LIMK-cofilin pathway, illustrating how Rho/ROCK can influence gene expression through its effects on the cytoskeleton and subsequent activation of transcription factors [220].

6.2 Interactions and Regulatory Loops With the PI3K/Akt Pathway, Including the Role of PTEN

The phosphoinositide 3-kinase (PI3K)/Akt/mTOR pathway is a key intracellular signaling cascade that regulates cell metabolism, migration, immune function, and survival [221]. A well-documented point of crosstalk between Rho/ROCK and PI3K/Akt involves the phosphatase and




Fig. 3. Rho-kinase activation of various cytoskeleton pathways. Rho GTPases, including RhoA, get activated through a sequential process of guanine nucleotide exchange factors (GEFs) that catalyze the exchange of GDP for GTP, followed by the inactivation of GTPase-activating proteins (GAPs). Rho-kinase is an effector form of Rho. Many other substrates of Rho-kinase include myosin light chain (MLC), MLC phosphatase (MLCP), ezrin/radixin/moesin (ERM), adducin, and LIM-kinases. Endothelial NO synthase (eNOS), guanine nucleotide (GDI), G-protein-coupled receptor (GPCR), collapsing response mediator protein2 (CRMP2), and ezrin/radixin/moesin (ERM). Re-created from [130]. Created in BioRender™.

tensin homolog (PTEN) [125,222]. ROCK-mediated activation of PTEN can lead to a decrease in nitric oxide (NO) production, which in turn reduces the survival of endothelial cells [223,224]. Both Rho/ROCK and PI3K/Akt pathways can be activated by standard upstream signals and receptors, such as G-protein coupled receptors (GPCRs) and receptor tyrosine kinases (RTKs), further illustrating their interconnectedness [211,225,226]. The complex interplay and crosstalk between pathways like Rho/ROCK, TGF- β , Wnt/ β -Catenin, NF- κ B, and PI3K-AKT-mTOR are also explored in the context of cataract formation, where disruptions in these signaling networks contribute to protein aggregation and lens opacification [227,228].

6.3 Other Significant Crosstalk Mechanisms Relevant to Cellular Function and Disease

6.3.1 NF- κ B Signaling

Both ROCK and NF- κ B can be activated by lysophosphatidic acid (LPA), a known inflammation mediator [229].

NF- κ B has been shown to act downstream of ROCK to mediate LPA-induced expression of specific inflammatory cytokines, such as monocyte chemotactic protein-1 (MCP-1). In the context of thrombin-induced ICAM-1 expression, the RhoA/ROCK pathway increases the phosphorylation of I κ B kinase (IKK), leading to I κ B α degradation and subsequent activation and nuclear translocation of NF- κ B.

6.3.2 TGF- β Signaling

Transforming growth factor-beta 2 (TGF- β 2) is a profibrotic cytokine that significantly activates the Rho-ROCK pathway in trabecular meshwork (TM) cells [165, 170,196,197,217]. This activation leads to increased cell stiffness and ECM remodeling, which are crucial pathological changes observed in glaucoma.

6.3.3 Myelin-Associated Inhibitors and Glial Scarring

In the central nervous system (CNS), myelin-associated inhibitory factors such as Nogo, Myelin-

Associated Glycoprotein (MAG), Oligodendrocyte-Myelin Glycoprotein (OMgp), and chondroitin sulfate proteoglycans (CSPGs) released from reactive astrocytes in glial scars activate the RhoA/ROCK pathway in neurons [230]. This activation inhibits axon growth and causes growth cone collapse, contributing to the limited regeneration capacity after CNS injury.

Here we present the complex *network* of cellular signaling, showing that Rho/ROCK signaling does not work alone. It is demonstrated that Rho/ROCK signaling is closely connected with other major pathways. The specific examples of Rho/ROCK affecting MAPK/ERK and, most notably, the PI3K/Akt pathway through PTEN, reveal advanced regulatory loops and overall cellular functions. This detailed mechanism is crucial for understanding the wide-ranging effects of RKI therapies and for predicting potential off-target effects or benefits from targeting this pathway. It also suggests that treatment strategies must consider the whole signaling network to prevent unintended effects and to improve treatment success by affecting multiple pathways.

7. Therapeutic Implications and Future Directions

Interestingly, in the late 1990s, a report was published using a broad spectrum serine-threonine kinase inhibitor, H-7, that demonstrated an increase in outflow facility in monkeys [231]. Although H-7 is a non-selective ROCK inhibitor with low potency against ROCK, this paper mentioned Rho A but did not mention ROCK. Furthermore, extensive research on Rho GTPase and Rho kinase signaling—particularly its role in TM tissue contractility, IOP regulation, and glaucoma—has paved the way for significant translational advancements, especially in ophthalmology [144,179,184,187,232].

7.1 Rho Kinase Inhibitors (RKIs) as a Novel Class of Glaucoma Therapeutics

The ROCK inhibitors (RKIs) are an emerging and promising class of anti-glaucoma drugs that specifically target the diseased trabecular outflow pathway, improving AH outflow through the conventional route. Ripasudil (K-115) [233–236] and Netarsudil (AR-13324) [232,237–242] are two leading RKIs that have received clinical approval for glaucoma treatment in Japan and the United States, respectively.

7.2 Mechanism of Action in IOP Reduction

RKIs mainly lower IOP by relaxing the TM and SC cells [156,165,184,187,243–248]. This relaxation is achieved by decreasing actin stress fiber density, disassembling focal adhesions, and lowering cell stiffness and tension in TM and SC cells. On a molecular level, this involves directly inhibiting MLC phosphorylation or increasing MLCP activity, leading to MLC dephosphorylation and

reduced actomyosin contractility. Most recently, it has been shown that ROCK inhibitors target the ECM by lowering the traction forces sensed by the TM cells [249,250]. The overall effect is an increase in intercellular space within the TM and improved permeability, which facilitates AH outflow. Netarsudil also inhibits norepinephrine transport (NET), potentially contributing to IOP reduction by decreasing AH production through preventing norepinephrine reuptake at noradrenergic synapses [237,238]. Another mechanism includes lowering episcleral venous pressure [239,251].

7.3 Clinical Efficacy, Safety Profiles, and Common Adverse Effects

Clinical trials have demonstrated that RKIs are safe and efficacious, showing non-inferiority when compared to traditional anti-glaucoma medications such as beta-blockers and prostaglandins (Table 4, Ref. [199,200,232–235,237–241,251–257]). They are effective as monotherapy and, importantly, show enhanced efficacy when combined with other hypotensive medications. The Netarsudil/latanoprost fixed-dose combination has demonstrated superior IOP reduction compared to individual components [252,258–260]. Common adverse effects reported include conjunctival hyperemia (the most frequent, affecting ~53% of patients with Netarsudil), corneal verticillata (cornea staining), conjunctival hemorrhage, instillation site pain, conjunctivitis, and blepharitis. Most of these effects are generally mild, self-limiting, and temporary [253,261–264]. The very mechanism that makes RKIs effective for glaucoma—by relaxing the TM outflow pathways to lower IOP—also leads to the relaxation of conjunctival blood vessels, causing them to dilate and resulting in conjunctival hyperemia. Corneal verticillata caused by RKIs is typically asymptomatic and does not affect vision. It is also reversible, with the deposits usually resolving over time after the medication is discontinued [253,261–265].

This table summarizes key therapeutic agents, their mechanisms, and clinical considerations, making it highly useful for experts who want to quickly understand the practical aspects of Rho/ROCK research in glaucoma management.

7.4 Neuroprotective Potential of RKIs in Glaucoma

Beyond their IOP-lowering capabilities, RKIs offer significant neuroprotective properties, which is a crucial advantage in the comprehensive management of glaucoma, a neurodegenerative disease. This dual benefit of IOP lowering and neuroprotection addresses both the primary risk factor and the neurodegenerative component of glaucoma, offering a more holistic therapeutic strategy [266–268]. The mechanisms of neuroprotection are summarized in Sections 7.4.1–7.4.4.

Table 4. Rho kinase inhibitors in glaucoma: mechanism of action and clinical aspects.

Drug (approval status)	Primary mechanism of IOP reduction	Additional ocular benefits	Common adverse effects	Reference
Ripasudil (approved Japan)	Relaxation of trabecular meshwork (TM) and Schlemm's canal (SC) cells by inhibiting MLC phosphorylation and MLCP inhibition, reducing actomyosin contractility, increasing intercellular spaces	Neuroprotection (RGC survival, axon regeneration), improved ocular blood flow, anti-fibrotic effects	Primarily conjunctival hyperemia (redness), often mild and temporary, along with blepharitis (eyelid inflammation) and allergic conjunctivitis	[199,200,233–235,251,253]
Netarsudil (approved USA)	Relaxation of TM and SC cells (like Ripasudil); also inhibits norepinephrine transporter (NET) to reduce AH formation	Neuroprotection (RGC survival, axon regeneration), improved ocular blood flow, anti-fibrotic effects	Conjunctival hyperemia (~53%), corneal verticillate, instillation site pain, conjunctival hemorrhages, blepharitis, conjunctivitis	[232,237–241,252,254–257]

7.4.1 Retinal Ganglion Cell (RGC) Survival and Axon Regeneration

RKIs have been shown to enhance RGC survival and promote RGC axon regeneration in various animal models of optic nerve injury (e.g., optic nerve crush injury, experimental glaucoma). They achieve this by suppressing ROCK signaling in the retina and optic nerve, which is typically activated by myelin-associated axon growth inhibitors (like Nogo, MAG, OMgp) and components of the glial scar (like chondroitin sulfate proteoglycans, CSPGs) that impede axonal regeneration. RKIs can effectively reverse these inhibitory effects, promoting axonal sprouting and functional recovery [269,270].

7.4.2 Improvement of Ocular Blood Flow

RKIs improve ocular blood flow, particularly to the optic nerve head, by promoting vasodilation and reducing vasoconstriction often mediated by endothelin-1. Impaired ocular blood flow is a recognized factor in glaucoma pathogenesis [186,271,272].

7.4.3 Alleviation of Cytotoxicity

RKIs protect retinal ganglion cells against neurotoxic injury induced by agents like N-methyl-d-aspartate and mitigate damage from ischemic reperfusion injury in animal models [199,201,243].

7.4.4 Anti-apoptotic Effects

While not explicitly detailed as a direct mechanism in all studies, the general involvement of ROCK in cell apoptosis and its crosstalk with pro-survival pathways like PI3K/Akt via PTEN suggests an indirect influence on RGC survival by modulating the balance between pro-survival and pro-apoptotic signals [273,274].

7.5 Emerging Applications of Rho/ROCK Modulation in Other Ocular Diseases and Systemic Diseases

The therapeutic potential of Rho/ROCK modulation extends beyond glaucoma, underscoring its widespread pathophysiological relevance.

7.5.1 Corneal Healing and Endothelial Regeneration

RKIs have demonstrated efficacy in improving corneal wound healing and promoting corneal endothelial cell differentiation and regeneration, making them promising therapeutic agents for corneal diseases [135,275–278].

7.5.2 Vitreoretinal Diseases

Rho/ROCK pathway activation is implicated in the pathophysiology of various retinal and vitreous diseases, including diabetic retinopathy (DR), age-related macular degeneration (AMD), and proliferative vitreoretinopathy (PVR). RKIs are being explored as potential therapeutic targets for these conditions due to their anti-fibrotic and anti-angiogenic effects [279–282].

7.5.3 Anti-fibrotic Agents

RKIs serve as potent anti-scarring agents by inhibiting the transdifferentiation of fibroblasts into myofibroblasts. This property is highly relevant in glaucoma surgery (to prevent bleb scarring, which is a common cause of surgical failure) and in conditions like PVR [283–286].

7.5.4 Systemic Diseases

Beyond ophthalmology, dysregulation of RhoA/ROCK signaling is linked to a wide range of age-related and smooth muscle-related systemic diseases, including hypertension, atherosclerosis, heart failure, diabetes, and various neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease [287–290].

7.6 Challenges and Future Research Avenues

This section highlights the significant translational impact of Rho/ROCK research, demonstrating how fundamental scientific understanding has led to tangible clinical advancements. Despite the significant advancements, several challenges and promising future research avenues exist for Rho/ROCK modulation.

7.6.1 Selectivity

A notable challenge in RKİ therapy is the current lack of highly selective Rho kinase inhibitors. Given the ubiquitous expression and pleiotropic functions of ROCKs, non-specific inhibition could lead to undesirable systemic consequences. Future research aims to develop more isoform-specific inhibitors to minimize off-target effects.

7.6.2 Drug Delivery Systems

For neuroprotective effects, particularly targeting RGCs and the optic nerve, traditional topical or oral routes may be insufficient due to anatomical barriers. Novel drug delivery systems, such as sustained-release implants or exosome-based delivery, are being explored to ensure effective drug concentrations at the target site and to improve patient compliance and tolerability.

7.6.3 Long-term Clinical Outcomes

While initial clinical trials show promise, further independent, large-scale, prospective randomized controlled trials are essential to comprehensively elucidate the long-term therapeutic value and safety profiles of RKIs.

7.6.4 Optimal Dosage and Patient Selection

Ongoing research is needed to determine the optimal dosage regimens and identify specific patient populations that would benefit from RKİ therapies the most.

7.6.5 Combination Therapies

The demonstrated success of fixed-dose combinations (e.g., Netarsudil/latanoprost) suggests a future direction in combining RKIs with existing glaucoma treatments to achieve enhanced efficacy and broader therapeutic benefits.

Novel drugs targeting specific pathways relevant to mechanosensing and mechanotransduction, which are directly tied to the Rho/ROCK pathway and play a role in elevating IOP, can be pharmacologically targeted. These can be the focal adhesions, integrins, G-proteins, to name a few.

8. Conclusion

The Rho GTPase and ROCK signaling pathway is a highly influential regulatory axis in cellular and tissue biology. It fundamentally controls actomyosin contractility and cytoskeletal dynamics, as well as its adaptive response to mechanical forces through mechanotransduction. The success of RKIs in glaucoma therapy highlights the clinical significance of this research. Drugs like Ripasudil and Netarsudil have demonstrated considerable effectiveness in lowering IOP by relaxing the conventional outflow pathway, offering a new approach compared to traditional glaucoma treatments. The combined benefit of IOP reduction and neuroprotection represents a significant advancement, addressing both the primary risk factor and the neurodegenerative aspect of glaucoma, thus providing a comprehen-

sive treatment strategy. The balanced discussion of clinical efficacy alongside common side effects reflects a genuine clinical perspective. Exploring applications beyond glaucoma emphasizes the wide therapeutic potential of modulating this pathway, indicating its broad relevance across various diseases. Finally, recognizing the challenges highlights key areas for future research and innovation with new drug targets. Future efforts will likely focus on refining these targeted approaches and discovering new strategies to leverage this fundamental signaling pathway for improved patient outcomes.

Author Contributions

Conceptualization: PPP, SR. Writing—original draft preparation: PPP, SR. Figure preparation: SR, PPP. Writing: review and editing: SR, PPP. Supervision: PPP. Project administration: PPP. Funding acquisition: PPP. Both authors read and approved the final manuscript. Both authors have participated sufficiently in the work and agreed to be accountable for all aspects of the work.

Ethics Approval and Consent to Participate

Not applicable.

Acknowledgment

We want to thank all the members of the Pattabiraman lab for their valuable input and thoughtful discussions. The figures were created using BioRender (<https://BioRender.com/oytvb7f>, <https://BioRender.com/j7tv0f4> and <https://BioRender.com/r9wrta>).

Funding

This work was supported by the National Institutes of Health/National Eye Institute R01EY029320, R01EY035412, and R01EY036107 (PPP); an award from the Ralph W. and Grace M. Showalter Research Trust and the Indiana University School of Medicine (PPP); the RPB Departmental Pilot Grant (PPP), Glick Research Endowment Funds (PPP), and a Challenge grant from Research to Prevent Blindness to IU.

Conflict of Interest

The authors declare that they have no conflicts of interests.

References

- [1] Jaffe AB, Hall A. Rho GTPases: biochemistry and biology. *Annual Review of Cell and Developmental Biology*. 2005; 21: 247–269. <https://doi.org/10.1146/annurev.cellbio.21.020604.150721>.
- [2] Hall A. Rho family GTPases. *Biochemical Society Transactions*. 2012; 40: 1378–1382. <https://doi.org/10.1042/BST20120103>.
- [3] Schmidt A, Hall A. Guanine nucleotide exchange factors for Rho GTPases: turning on the switch. *Genes & Development*. 2002; 16: 1587–1609. <https://doi.org/10.1101/gad.1003302>.

[4] Dvorsky R, Ahmadian MR. Always look on the bright side of Rho: structural implications for a conserved intermolecular interface. *EMBO Reports*. 2004; 5: 1130–1136. <https://doi.org/10.1038/sj.embor.7400293>.

[5] Lin Y, Zheng Y. Structural Dynamics of Rho GTPases. *Journal of Molecular Biology*. 2025; 437: 168919. <https://doi.org/10.1016/j.jmb.2024.168919>.

[6] Watanabe N, Kato T, Fujita A, Ishizaki T, Narumiya S. Co-operation between mDia1 and ROCK in Rho-induced actin reorganization. *Nature Cell Biology*. 1999; 1: 136–143. <https://doi.org/10.1038/11056>.

[7] Vega FM, Colomba A, Reymond N, Thomas M, Ridley AJ. RhoB regulates cell migration through altered focal adhesion dynamics. *Open Biology*. 2012; 2: 120076. <https://doi.org/10.1098/rsob.120076>.

[8] Vega FM, Fruhwirth G, Ng T, Ridley AJ. RhoA and RhoC have distinct roles in migration and invasion by acting through different targets. *The Journal of Cell Biology*. 2011; 193: 655–665. <https://doi.org/10.1083/jcb.201011038>.

[9] Mino A, Troeger A, Brendel C, Cantor A, Harris C, Ciuculescu MF, et al. RhoH participates in a multi-protein complex with the zinc finger protein kaiso that regulates both cytoskeletal structures and chemokine-induced T cells. *Small GTPases*. 2018; 9: 260–273. <https://doi.org/10.1080/21541248.2016.1220780>.

[10] Bagrodia S, Cerione RA. Pak to the future. *Trends in Cell Biology*. 1999; 9: 350–355. [https://doi.org/10.1016/s0962-8924\(99\)01618-9](https://doi.org/10.1016/s0962-8924(99)01618-9).

[11] Singh A, Karnoub AE, Palmby TR, Lengyel E, Sondek J, Der CJ. Rac1b, a tumor associated, constitutively active Rac1 splice variant, promotes cellular transformation. *Oncogene*. 2004; 23: 9369–9380. <https://doi.org/10.1038/sj.onc.1208182>.

[12] Arana E, Vehlow A, Harwood NE, Vigorito E, Henderson R, Turner M, et al. Activation of the small GTPase Rac2 via the B cell receptor regulates B cell adhesion and immunological-synapse formation. *Immunity*. 2008; 28: 88–99. <https://doi.org/10.1016/j.immuni.2007.12.003>.

[13] Hajdo-Milasinovic A, van der Kammen RA, Moneva Z, Collard JG. Rac3 inhibits adhesion and differentiation of neuronal cells by modifying GIT1 downstream signaling. *Journal of Cell Science*. 2009; 122: 2127–2136. <https://doi.org/10.1242/jcs.039958>.

[14] Vignal E, Blangy A, Martin M, Gauthier-Rouvière C, Fort P. Kinectin is a key effector of RhoG microtubule-dependent cellular activity. *Molecular and Cellular Biology*. 2001; 21: 8022–8034. <https://doi.org/10.1128/MCB.21.23.8022-8034.2001>.

[15] Rohatgi R, Ma L, Miki H, Lopez M, Kirchhausen T, Takenawa T, et al. The interaction between N-WASP and the Arp2/3 complex links Cdc42-dependent signals to actin assembly. *Cell*. 1999; 97: 221–231. [https://doi.org/10.1016/s0092-8674\(00\)80732-1](https://doi.org/10.1016/s0092-8674(00)80732-1).

[16] Murphy GA, Solski PA, Jillian SA, Pérez de la Ossa P, D'Eustachio P, Der CJ, et al. Cellular functions of TC10, a Rho family GTPase: regulation of morphology, signal transduction and cell growth. *Oncogene*. 1999; 18: 3831–3845. <https://doi.org/10.1038/sj.onc.1202758>.

[17] Wilson E, Leszczynska K, Poulter NS, Edelmann F, Salisbury VA, Noy PJ, et al. RhoJ interacts with the GIT-PIX complex and regulates focal adhesion disassembly. *Journal of Cell Science*. 2014; 127: 3039–3051. <https://doi.org/10.1242/jcs.140434>.

[18] Aspenström P. Atypical Rho GTPases RhoD and Rif integrate cytoskeletal dynamics and membrane trafficking. *Biological Chemistry*. 2014; 395: 477–484. <https://doi.org/10.1515/hsz-2013-0296>.

[19] Hodge RG, Ridley AJ. Regulation and functions of RhoU and RhoV. *Small GTPases*. 2020; 11: 8–15. <https://doi.org/10.1080/21541248.2017.1362495>.

[20] Li YH, Ghavampur S, Bondallaz P, Will L, Grenningloh G, Pu Schel AW. Rnd1 regulates axon extension by enhancing the microtubule destabilizing activity of SCG10. *The Journal of Biological Chemistry*. 2009; 284: 363–371. <https://doi.org/10.1074/jbc.M808126200>.

[21] Fujita H, Katoh H, Ishikawa Y, Mori K, Negishi M. Rapostlin is a novel effector of Rnd2 GTPase inducing neurite branching. *The Journal of Biological Chemistry*. 2002; 277: 45428–45434. <https://doi.org/10.1074/jbc.M208090200>.

[22] Katoh H, Harada A, Mori K, Negishi M. Socius is a novel Rnd GTPase-interacting protein involved in disassembly of actin stress fibers. *Molecular and Cellular Biology*. 2002; 22: 2952–2964. <https://doi.org/10.1128/MCB.22.9.2952-2964.2002>.

[23] Ji W, Rivero F. Atypical Rho GTPases of the RhoBTB Subfamily: Roles in Vesicle Trafficking and Tumorigenesis. *Cells*. 2016; 5: 28. <https://doi.org/10.3390/cells5020028>.

[24] Bobkov DE, Lukacheva AV, Gorb AI, Poljanskaya GG. Role of Rho family small GTPases in the regulation of normal and pathological processes. *Cell and Tissue Biology*. 2024; 18: 229–243. <https://doi.org/10.1134/S1990519X24700159>.

[25] Mosaddeghzadeh N, Ahmadian MR. The RHO Family GTPases: Mechanisms of Regulation and Signaling. *Cells*. 2021; 10: 1831. <https://doi.org/10.3390/cells10071831>.

[26] Etienne-Manneville S, Hall A. Rho GTPases in cell biology. *Nature*. 2002; 420: 629–635. <https://doi.org/10.1038/nature01148>.

[27] Marjoram RJ, Lessey EC, Burridge K. Regulation of RhoA activity by adhesion molecules and mechanotransduction. *Current Molecular Medicine*. 2014; 14: 199–208. <https://doi.org/10.2174/156652401466140128104541>.

[28] Nobes CD, Hall A. Rho, rac, and cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia. *Cell*. 1995; 81: 53–62. [https://doi.org/10.1016/0092-8674\(95\)90370-4](https://doi.org/10.1016/0092-8674(95)90370-4).

[29] Steffen A, Ladwein M, Dimchev GA, Hein A, Schwenkmezger L, Arens S, et al. Rac function is crucial for cell migration but is not required for spreading and focal adhesion formation. *Journal of Cell Science*. 2013; 126: 4572–4588. <https://doi.org/10.1242/jcs.118232>.

[30] Malasala S, Azimian F, Chen YH, Twiss JL, Boykin C, Akhtar SN, et al. Enabling systemic identification and functionality profiling for Cdc42 homeostatic modulators. *Communications Chemistry*. 2024; 7: 271. <https://doi.org/10.1038/s42004-024-01352-7>.

[31] Krugmann S, Jordens I, Gevaert K, Driessens M, Vandekerckhove J, Hall A. Cdc42 induces filopodia by promoting the formation of an IRS53:Mena complex. *Current Biology: CB*. 2001; 11: 1645–1655. [https://doi.org/10.1016/s0960-9822\(01\)00506-1](https://doi.org/10.1016/s0960-9822(01)00506-1).

[32] Castellano F, Montcourier P, Guillemot JC, Gouin E, Machesky L, Cossart P, et al. Inducible recruitment of Cdc42 or WASP to a cell-surface receptor triggers actin polymerization and filopodium formation. *Current Biology: CB*. 1999; 9: 351–360. [https://doi.org/10.1016/s0960-9822\(99\)80161-4](https://doi.org/10.1016/s0960-9822(99)80161-4).

[33] Van Aelst L, D'Souza-Schorey C. Rho GTPases and signaling networks. *Genes & Development*. 1997; 11: 2295–2322. <https://doi.org/10.1101/gad.11.18.2295>.

[34] Chi X, Wang S, Huang Y, Stamnes M, Chen JL. Roles of rho GTPases in intracellular transport and cellular transformation. *International Journal of Molecular Sciences*. 2013; 14: 7089–7108. <https://doi.org/10.3390/ijms14047089>.

[35] Zegers MM, Friedl P. Rho GTPases in collective cell migration. *Small GTPases*. 2014; 5: e28997. <https://doi.org/10.4161/sgrp.28997>.

[36] Dickson BJ. Rho GTPases in growth cone guidance. *Current Opinion in Neurobiology*. 2001; 11: 103–110. [https://doi.org/10.1016/s0959-4388\(00\)00180-x](https://doi.org/10.1016/s0959-4388(00)00180-x).

[37] Cernuda-Morollón E, Ridley AJ. Rho GTPases and leukocyte

adhesion receptor expression and function in endothelial cells. *Circulation Research*. 2006; 98: 757–767. <https://doi.org/10.1161/01.RES.0000210579.35304.d3>.

[38] Fukata M, Kaibuchi K. Rho-family GTPases in cadherin-mediated cell-cell adhesion. *Nature Reviews Molecular Cell Biology*. 2001; 2: 887–897. <https://doi.org/10.1038/35103068>.

[39] Verboon JM, Parkhurst SM. Rho family GTPases bring a familiar ring to cell wound repair. *Small GTPases*. 2015; 6: 1–7. <https://doi.org/10.4161/21541248.2014.992262>.

[40] Matsui T, Amano M, Yamamoto T, Chihara K, Nakafuku M, Ito M, *et al*. Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. *The EMBO Journal*. 1996; 15: 2208–2216.

[41] Croft DR, Olson MF. The Rho GTPase effector ROCK regulates cyclin A, cyclin D1, and p27kip1 levels by distinct mechanisms. *Molecular and Cellular Biology*. 2006; 26: 4612–4627. <https://doi.org/10.1128/MCB.02061-05>.

[42] Amano M, Nakayama M, Kaibuchi K. Rho-kinase/ROCK: A key regulator of the cytoskeleton and cell polarity. *Cytoskeleton (Hoboken, N.J.)*. 2010; 67: 545–554. <https://doi.org/10.1002/cm.20472>.

[43] Julian L, Olson MF. Rho-associated coiled-coil containing kinases (ROCK): structure, regulation, and functions. *Small GTPases*. 2014; 5: e29846. <https://doi.org/10.4161/sgtp.29846>.

[44] Riento K, Ridley AJ. Rocks: multifunctional kinases in cell behaviour. *Nature Reviews Molecular Cell Biology*. 2003; 4: 446–456. <https://doi.org/10.1038/nrm1128>.

[45] Wang Y, Zheng XR, Riddick N, Bryden M, Baur W, Zhang X, *et al*. ROCK isoform regulation of myosin phosphatase and contractility in vascular smooth muscle cells. *Circulation Research*. 2009; 104: 531–540. <https://doi.org/10.1161/CIRCRESAHA.108.188524>.

[46] Murthy KS. Signaling for contraction and relaxation in smooth muscle of the gut. *Annual Review of Physiology*. 2006; 68: 345–374. <https://doi.org/10.1146/annurev.physiol.68.040504.094707>.

[47] Olson MF. Rho GTPases, their post-translational modifications, disease-associated mutations and pharmacological inhibitors. *Small GTPases*. 2018; 9: 203–215. <https://doi.org/10.1080/21541248.2016.1218407>.

[48] Nakagawa O, Fujisawa K, Ishizaki T, Saito Y, Nakao K, Narumiya S. ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice. *FEBS Letters*. 1996; 392: 189–193. [https://doi.org/10.1016/0014-5793\(96\)00811-3](https://doi.org/10.1016/0014-5793(96)00811-3).

[49] Zhang JY, Dong HS, Oqani RK, Lin T, Kang JW, Jin DI. Distinct roles of ROCK1 and ROCK2 during development of porcine preimplantation embryos. *Reproduction (Cambridge, England)*. 2014; 148: 99–107. <https://doi.org/10.1530/REP-13-0556>.

[50] Saadeldin IM, Tukur HA, Aljumaah RS, Sindi RA. Rocking the Boat: The Decisive Roles of Rho Kinases During Oocyte, Blastocyst, and Stem Cell Development. *Frontiers in Cell and Developmental Biology*. 2021; 8: 616762. <https://doi.org/10.3389/fcell.2020.616762>.

[51] Jaiswal M, Dvorsky R, Ahmadian MR. Deciphering the molecular and functional basis of Dbl family proteins: a novel systematic approach toward classification of selective activation of the Rho family proteins. *The Journal of Biological Chemistry*. 2013; 288: 4486–4500. <https://doi.org/10.1074/jbc.M112.429746>.

[52] Schaefer A, Reinhard NR, Hordijk PL. Toward understanding RhoGTPase specificity: structure, function and local activation. *Small GTPases*. 2014; 5: 6. <https://doi.org/10.4161/21541248.2014.968004>.

[53] Rojas AM, Fuentes G, Rausell A, Valencia A. The Ras protein superfamily: evolutionary tree and role of conserved amino acids. *The Journal of Cell Biology*. 2012; 196: 189–201. <https://doi.org/10.1083/jcb.201103008>.

[54] Roberts PJ, Mitin N, Keller PJ, Chenette EJ, Madigan JP, Curran RO, *et al*. Rho Family GTPase modification and dependence on CAAX motif-signal posttranslational modification. *The Journal of Biological Chemistry*. 2008; 283: 25150–25163. <https://doi.org/10.1074/jbc.M800882200>.

[55] Mayer T, Meyer M, Janning A, Schiedel AC, Barnekow A. A mutant form of the rho protein can restore stress fibers and adhesion plaques in v-src transformed fibroblasts. *Oncogene*. 1999; 18: 2117–2128. <https://doi.org/10.1038/sj.onc.1202537>.

[56] Chen S, Zhang Z, Zhang Y, Choi T, Zhao Y. Activation Mechanism of RhoA Caused by Constitutively Activating Mutations G14V and Q63L. *International Journal of Molecular Sciences*. 2022; 23: 15458. <https://doi.org/10.3390/ijms232415458>.

[57] Qiu RG, Chen J, McCormick F, Symons M. A role for Rho in Ras transformation. *Proceedings of the National Academy of Sciences of the United States of America*. 1995; 92: 11781–11785. <https://doi.org/10.1073/pnas.92.25.11781>.

[58] Ghosh PM, Ghosh-Choudhury N, Moyer ML, Mott GE, Thomas CA, Foster BA, *et al*. Role of RhoA activation in the growth and morphology of a murine prostate tumor cell line. *Oncogene*. 1999; 18: 4120–4130. <https://doi.org/10.1038/sj.onc.1202792>.

[59] Wei Y, Zhang Y, Derewenda U, Liu X, Minor W, Nakamoto RK, *et al*. Crystal structure of RhoA-GDP and its functional implications. *Nature Structural Biology*. 1997; 4: 699–703. <https://doi.org/10.1038/nsb0997-699>.

[60] Soundararajan M, Turnbull A, Fedorov O, Johansson C, Doyle DA. RhoB can adopt a Mg²⁺ free conformation prior to GEF binding. *Proteins*. 2008; 72: 498–505. <https://doi.org/10.1002/prot.22017>.

[61] Dias SMG, Cerione RA. X-ray crystal structures reveal two activated states for RhoC. *Biochemistry*. 2007; 46: 6547–6558. <https://doi.org/10.1021/bi700035p>.

[62] Vetter IR, Wittinghofer A. The guanine nucleotide-binding switch in three dimensions. *Science (New York, N.Y.)*. 2001; 294: 1299–1304. <https://doi.org/10.1126/science.1062023>.

[63] Kumawat A, Chakrabarty S, Kulkarni K. Nucleotide Dependent Switching in Rho GTPase: Conformational Heterogeneity and Competing Molecular Interactions. *Scientific Reports*. 2017; 7: 45829. <https://doi.org/10.1038/srep45829>.

[64] Schmidt G, Sehr P, Wilm M, Selzer J, Mann M, Aktories K. Gln 63 of Rho is deamidated by *Escherichia coli* cytotoxic necrotizing factor-1. *Nature*. 1997; 387: 725–729. <https://doi.org/10.1038/42735>.

[65] Wennerberg K, Rossman KL, Der CJ. The Ras superfamily at a glance. *Journal of Cell Science*. 2005; 118: 843–846. <https://doi.org/10.1242/jcs.01660>.

[66] Cherfils J, Zeghouf M. Regulation of small GTPases by GEFs, GAPs, and GDIs. *Physiological Reviews*. 2013; 93: 269–309. <https://doi.org/10.1152/physrev.00003.2012>.

[67] Wittinghofer A, Vetter IR. Structure-function relationships of the G domain, a canonical switch motif. *Annual Review of Biochemistry*. 2011; 80: 943–971. <https://doi.org/10.1146/annurev-biochem-062708-134043>.

[68] Rando RR. Chemical biology of protein isoprenylation/methylation. *Biochimica et Biophysica Acta*. 1996; 1300: 5–16. [https://doi.org/10.1016/0005-2760\(95\)00233-2](https://doi.org/10.1016/0005-2760(95)00233-2).

[69] Hori Y, Kikuchi A, Isomura M, Katayama M, Miura Y, Fujioka H, *et al*. Post-translational modifications of the C-terminal region of the rho protein are important for its interaction with membranes and the stimulatory and inhibitory GDP/GTP exchange proteins. *Oncogene*. 1991; 6: 515–522.

[70] Whitehead IP, Campbell S, Rossman KL, Der CJ. Dbl family proteins. *Biochimica et Biophysica Acta*. 1997; 1332: F1–F23. [https://doi.org/10.1016/s0304-419x\(96\)00040-6](https://doi.org/10.1016/s0304-419x(96)00040-6).

[71] Cerione RA, Zheng Y. The Dbl family of oncogenes. *Current*

Opinion in Cell Biology. 1996; 8: 216–222. [https://doi.org/10.1016/s0955-0674\(96\)80068-8](https://doi.org/10.1016/s0955-0674(96)80068-8).

[72] Amin E, Jaiswal M, Derewenda U, Reis K, Nouri K, Koessmeier KT, *et al.* Deciphering the Molecular and Functional Basis of RHOGAP Family Proteins: A SYSTEMATIC APPROACH TOWARD SELECTIVE INACTIVATION OF RHO FAMILY PROTEINS. *The Journal of Biological Chemistry*. 2016; 291: 20353–20371. <https://doi.org/10.1074/jbc.M116.736967>.

[73] Garcia-Mata R, Boulter E, Burridge K. The ‘invisible hand’: regulation of RHO GTPases by RHOGDI. *Nature Reviews Molecular Cell Biology*. 2011; 12: 493–504. <https://doi.org/10.1038/nrm3153>.

[74] Dovas A, Couchman JR. RhoGDI: multiple functions in the regulation of Rho family GTPase activities. *The Biochemical Journal*. 2005; 390: 1–9. <https://doi.org/10.1042/BJ20050104>.

[75] Cho HJ, Kim JT, Baek KE, Kim BY, Lee HG. Regulation of Rho GTPases by RhoGDI in Human Cancers. *Cells*. 2019; 8: 1037. <https://doi.org/10.3390/cells8091037>.

[76] Tnimov Z, Guo Z, Gambin Y, Nguyen UTT, Wu YW, Abankwa D, *et al.* Quantitative analysis of prenylated RhoA interaction with its chaperone, RhoGDI. *The Journal of Biological Chemistry*. 2012; 287: 26549–26562. <https://doi.org/10.1074/jbc.M112.371294>.

[77] Navarro-Lérida I, Sánchez-Álvarez M, Del Pozo MÁ. Post-Translational Modification and Subcellular Compartmentalization: Emerging Concepts on the Regulation and Physiopathological Relevance of RhoGTPases. *Cells*. 2021; 10: 1990. <https://doi.org/10.3390/cells10081990>.

[78] Ahearn IM, Haigis K, Bar-Sagi D, Philips MR. Regulating the regulator: post-translational modification of RAS. *Nature Reviews Molecular Cell Biology*. 2011; 13: 39–51. <https://doi.org/10.1038/nrm3255>.

[79] Chuang HH, Liang SW, Chang ZF, Lee HH. Ser1333 phosphorylation indicates ROCKI activation. *Journal of Biomedical Science*. 2013; 20: 83. <https://doi.org/10.1186/1423-0127-20-83>.

[80] Chuang HH, Yang CH, Tsay YG, Hsu CY, Tseng LM, Chang ZF, *et al.* ROCKII Ser1366 phosphorylation reflects the activation status. *The Biochemical Journal*. 2012; 443: 145–151. <https://doi.org/10.1042/BJ20111839>.

[81] Duman JG, Mulherkar S, Tu YK, X Cheng J, Tolias KF. Mechanisms for spatiotemporal regulation of Rho-GTPase signaling at synapses. *Neuroscience Letters*. 2015; 601: 4–10. <https://doi.org/10.1016/j.neulet.2015.05.034>.

[82] Armstrong MC, Weiß YR, Hoachlander-Hobby LE, Roy AA, Visco I, Moe A, *et al.* The biochemical mechanism of Rho GTPase membrane binding, activation and retention in activity patterning. *The EMBO Journal*. 2025; 44: 2620–2657. <https://doi.org/10.1038/s44318-025-00418-z>.

[83] Fritz RD, Pertz O. The dynamics of spatio-temporal Rho GTPase signaling: formation of signaling patterns. *F1000Research*. 2016; 5: F1000 Faculty Rev-749. <https://doi.org/10.12688/f1000research.7370.1>.

[84] Totsukawa G, Yamakita Y, Yamashiro S, Hartshorne DJ, Sasaki Y, Matsumura F. Distinct roles of ROCK (Rho-kinase) and MLCK in spatial regulation of MLC phosphorylation for assembly of stress fibers and focal adhesions in 3T3 fibroblasts. *The Journal of Cell Biology*. 2000; 150: 797–806. <https://doi.org/10.1083/jcb.150.4.797>.

[85] Pelosi M, Marampon F, Zani BM, Prudente S, Perlas E, Caputo V, *et al.* ROCK2 and its alternatively spliced isoform ROCK2m positively control the maturation of the myogenic program. *Molecular and Cellular Biology*. 2007; 27: 6163–6176. <https://doi.org/10.1128/MCB.01735-06>.

[86] Jacobs M, Hayakawa K, Swenson L, Bellon S, Fleming M, Taslimi P, *et al.* The structure of dimeric ROCK I reveals the mechanism for ligand selectivity. *The Journal of Biological Chemistry*. 2006; 281: 260–268. <https://doi.org/10.1074/jbc.C508847200>.

[87] Ishizaki T, Maekawa M, Fujisawa K, Okawa K, Iwamatsu A, Fujita A, *et al.* The small GTP-binding protein Rho binds to and activates a 160 kDa Ser/Thr protein kinase homologous to myotonic dystrophy kinase. *The EMBO Journal*. 1996; 15: 1885–1893.

[88] Amano M, Chihara K, Nakamura N, Kaneko T, Matsuura Y, Kaibuchi K. The COOH terminus of Rho-kinase negatively regulates rho-kinase activity. *The Journal of Biological Chemistry*. 1999; 274: 32418–32424. <https://doi.org/10.1074/jbc.274.45.32418>.

[89] Ishizaki T, Naito M, Fujisawa K, Maekawa M, Watanabe N, Saito Y, *et al.* p160ROCK, a Rho-associated coiled-coil forming protein kinase, works downstream of Rho and induces focal adhesions. *FEBS Letters*. 1997; 404: 118–124. [https://doi.org/10.1016/s0014-5793\(97\)00107-5](https://doi.org/10.1016/s0014-5793(97)00107-5).

[90] Dvorsky R, Blumenstein L, Vetter IR, Ahmadian MR. Structural insights into the interaction of ROCKI with the switch regions of RhoA. *The Journal of Biological Chemistry*. 2004; 279: 7098–7104. <https://doi.org/10.1074/jbc.M311911200>.

[91] Sebbagh M, Renvoizé C, Hamelin J, Riché N, Bertoglio J, Bréard J. Caspase-3-mediated cleavage of ROCK I induces MLC phosphorylation and apoptotic membrane blebbing. *Nature Cell Biology*. 2001; 3: 346–352. <https://doi.org/10.1038/35070019>.

[92] Sebbagh M, Hamelin J, Bertoglio J, Solary E, Bréard J. Direct cleavage of ROCK II by granzyme B induces target cell membrane blebbing in a caspase-independent manner. *The Journal of Experimental Medicine*. 2005; 201: 465–471. <https://doi.org/10.1084/jem.20031877>.

[93] Kamm KE, Stull JT. Dedicated myosin light chain kinases with diverse cellular functions. *The Journal of Biological Chemistry*. 2001; 276: 4527–4530. <https://doi.org/10.1074/jbc.R000028200>.

[94] Kitazawa T, Masuo M, Somlyo AP. G protein-activation inhibits smooth muscle MLC phosphatase to increase the contractile sensitivity to Ca²⁺. *Japanese Journal of Pharmacology*. 1992; 58 Suppl 2: 348P.

[95] Hartshorne DJ, Ito M, Erdödi F. Myosin light chain phosphatase: subunit composition, interactions and regulation. *Journal of Muscle Research and Cell Motility*. 1998; 19: 325–341. <https://doi.org/10.1023/a:1005385302064>.

[96] Schwartz M. Rho signalling at a glance. *Journal of Cell Science*. 2004; 117: 5457–5458. <https://doi.org/10.1242/jcs.01582>.

[97] Ito M, Ohmori T, Suzuki M, Furuya K, Morita F. A novel protein phosphatase-1 inhibitory protein potentiated by protein kinase C. Isolation from porcine aorta media and characterization. *Journal of Biochemistry*. 1995; 118: 1104–1107. <https://doi.org/10.1093/oxfordjournals.jbchem.a124993>.

[98] Ito M, Senba S, Morita F, Yazawa M. Molecular cloning of a novel phosphorylation-dependent inhibitory protein of protein phosphatase-1 (CPI17) in smooth muscle: its specific localization in smooth muscle. *FEBS Letters*. 1997; 410: 356–360. [https://doi.org/10.1016/s0014-5793\(97\)00657-1](https://doi.org/10.1016/s0014-5793(97)00657-1).

[99] Kimura K, Ito M, Amano M, Chihara K, Fukata Y, Nakafuku M, *et al.* Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). *Science (New York, N.Y.)*. 1996; 273: 245–248. <https://doi.org/10.1126/science.273.5272.245>.

[100] Thumke D, Watanabe S, Narumiya S. Physiological roles of Rho and Rho effectors in mammals. *European Journal of Cell Biology*. 2013; 92: 303–315. <https://doi.org/10.1016/j.ejcb.2013.09.002>.

[101] Sit ST, Manser E. Rho GTPases and their role in organizing the actin cytoskeleton. *Journal of Cell Science*. 2011; 124: 679–683.

<https://doi.org/10.1242/jcs.064964>.

[102] Kamm KE, Stull JT. The function of myosin and myosin light chain kinase phosphorylation in smooth muscle. *Annual Review of Pharmacology and Toxicology*. 1985; 25: 593–620. <https://doi.org/10.1146/annurev.pa.25.040185.003113>.

[103] Moussavi RS, Kelley CA, Adelstein RS. Phosphorylation of vertebrate nonmuscle and smooth muscle myosin heavy chains and light chains. *Molecular and Cellular Biochemistry*. 1993; 127-128: 219–227. <https://doi.org/10.1007/BF01076773>.

[104] Somlyo AP, Somlyo AV. Signal transduction and regulation in smooth muscle. *Nature*. 1994; 372: 231–236. <https://doi.org/10.1038/372231a0>.

[105] Arber S, Barbayannis FA, Hanser H, Schneider C, Stanyon CA, Bernard O, *et al.* Regulation of actin dynamics through phosphorylation of cofilin by LIM-kinase. *Nature*. 1998; 393: 805–809. <https://doi.org/10.1038/31729>.

[106] Casanova-Sepúlveda G, Boggon TJ. Regulation and signaling of the LIM domain kinases. *BioEssays: News and Reviews in Molecular, Cellular and Developmental Biology*. 2025; 47: e2400184. <https://doi.org/10.1002/bies.202400184>.

[107] Li F, Higgs HN. The mouse Formin mDia1 is a potent actin nucleation factor regulated by autoinhibition. *Current Biology*: CB. 2003; 13: 1335–1340. [https://doi.org/10.1016/s0960-9822\(03\)00540-2](https://doi.org/10.1016/s0960-9822(03)00540-2).

[108] DuFort CC, Paszek MJ, Weaver VM. Balancing forces: architectural control of mechanotransduction. *Nature Reviews Molecular Cell Biology*. 2011; 12: 308–319. <https://doi.org/10.1038/nrm3112>.

[109] Kureishi Y, Kobayashi S, Amano M, Kimura K, Kanaide H, Nakano T, *et al.* Rho-associated kinase directly induces smooth muscle contraction through myosin light chain phosphorylation. *The Journal of Biological Chemistry*. 1997; 272: 12257–12260. <https://doi.org/10.1074/jbc.272.19.12257>.

[110] Hudson CA, Heesom KJ, López Bernal A. Phasic contractions of isolated human myometrium are associated with Rho-kinase (ROCK)-dependent phosphorylation of myosin phosphatase-targeting subunit (MYPT1). *Molecular Human Reproduction*. 2012; 18: 265–279. <https://doi.org/10.1093/molehr/gar078>.

[111] Prunier C, Prudent R, Kapur R, Sadoul K, Lafanechère L. LIM kinases: cofilin and beyond. *Oncotarget*. 2017; 8: 41749–41763. <https://doi.org/10.18632/oncotarget.16978>.

[112] Kolosova IA, Ma SF, Adyshev DM, Wang P, Ohba M, Natarajan V, *et al.* Role of CPI-17 in the regulation of endothelial cytoskeleton. *American Journal of Physiology. Lung Cellular and Molecular Physiology*. 2004; 287: L970–L980. <https://doi.org/10.1152/ajplung.00398.2003>.

[113] Higashida C, Miyoshi T, Fujita A, Oceguera-Yanez F, Monypenny J, Andou Y, *et al.* Actin polymerization-driven molecular movement of mDia1 in living cells. *Science (New York, N.Y.)*. 2004; 303: 2007–2010. <https://doi.org/10.1126/science.1093923>.

[114] Tsukita S, Yonemura S. ERM (ezrin/radixin/moesin) family: from cytoskeleton to signal transduction. *Current Opinion in Cell Biology*. 1997; 9: 70–75. [https://doi.org/10.1016/s0955-0674\(97\)80154-8](https://doi.org/10.1016/s0955-0674(97)80154-8).

[115] Li X, Matsuoka Y, Bennett V. Adducin preferentially recruits spectrin to the fast growing ends of actin filaments in a complex requiring the MARCKS-related domain and a newly defined oligomerization domain. *The Journal of Biological Chemistry*. 1998; 273: 19329–19338. <https://doi.org/10.1074/jbc.273.30.19329>.

[116] Fukata Y, Oshiro N, Kinoshita N, Kawano Y, Matsuoka Y, Bennett V, *et al.* Phosphorylation of adducin by Rho-kinase plays a crucial role in cell motility. *The Journal of Cell Biology*. 1999; 145: 347–361. <https://doi.org/10.1083/jcb.145.2.347>.

[117] Hooley R, Yu CY, Symons M, Barber DL. G alpha 13 stimulates Na⁺-H⁺ exchange through distinct Cdc42-dependent and RhoA-dependent pathways. *The Journal of Biological Chemistry*. 1996; 271: 6152–6158. <https://doi.org/10.1074/jbc.271.11.6152>.

[118] Hol EM, Capetanaki Y. Type III Intermediate Filaments Desmin, Glial Fibrillary Acidic Protein (GFAP), Vimentin, and Peripherin. *Cold Spring Harbor Perspectives in Biology*. 2017; 9: a021642. <https://doi.org/10.1101/cshperspect.a021642>.

[119] Goto H, Kosako H, Tanabe K, Yanagida M, Sakurai M, Amano M, *et al.* Phosphorylation of vimentin by Rho-associated kinase at a unique amino-terminal site that is specifically phosphorylated during cytokinesis. *The Journal of Biological Chemistry*. 1998; 273: 11728–11736. <https://doi.org/10.1074/jbc.273.19.11728>.

[120] Hashimoto R, Nakamura Y, Komai S, Kashiwagi Y, Tamura K, Goto T, *et al.* Site-specific phosphorylation of neurofilament-L is mediated by calcium/calmodulin-dependent protein kinase II in the apical dendrites during long-term potentiation. *Journal of Neurochemistry*. 2000; 75: 373–382. <https://doi.org/10.1046/j.1471-4159.2000.0750373.x>.

[121] Kosako H, Amano M, Yanagida M, Tanabe K, Nishi Y, Kaibuchi K, *et al.* Phosphorylation of glial fibrillary acidic protein at the same sites by cleavage furrow kinase and Rho-associated kinase. *The Journal of Biological Chemistry*. 1997; 272: 10333–10336. <https://doi.org/10.1074/jbc.272.16.10333>.

[122] Noguchi D, Watamura N, Nikkuni M, Saido TC, Goshima Y, Ohshima T. Involvement of CRMP2 Phosphorylation in Amyloid Beta-induced Tau Phosphorylation of Hippocampal Neurons in Alzheimer's Disease Mouse Model. *Molecular Neurobiology*. 2025; 62: 7413–7420. <https://doi.org/10.1007/s12035-025-04721-y>.

[123] Amano M, Kaneko T, Maeda A, Nakayama M, Ito M, Yamada T, *et al.* Identification of Tau and MAP2 as novel substrates of Rho-kinase and myosin phosphatase. *Journal of Neurochemistry*. 2003; 87: 780–790. <https://doi.org/10.1046/j.1471-4159.2003.02054.x>.

[124] Li Z, Dong X, Wang Z, Liu W, Deng N, Ding Y, *et al.* Regulation of PTEN by Rho small GTPases. *Nature Cell Biology*. 2005; 7: 399–404. <https://doi.org/10.1038/ncb1236>.

[125] Yang S, Kim HM. The RhoA-ROCK-PTEN pathway as a molecular switch for anchorage dependent cell behavior. *Biomaterials*. 2012; 33: 2902–2915. <https://doi.org/10.1016/j.biomaterials.2011.12.051>.

[126] Fukata Y, Amano M, Kaibuchi K. Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells. *Trends in Pharmacological Sciences*. 2001; 22: 32–39. [https://doi.org/10.1016/s0165-6147\(00\)01596-0](https://doi.org/10.1016/s0165-6147(00)01596-0).

[127] Dong M, Yan BP, Liao JK, Lam YY, Yip GWK, Yu CM. Rho-kinase inhibition: a novel therapeutic target for the treatment of cardiovascular diseases. *Drug Discovery Today*. 2010; 15: 622–629. <https://doi.org/10.1016/j.drudis.2010.06.011>.

[128] Noma K, Oyama N, Liao JK. Physiological role of ROCKs in the cardiovascular system. *American Journal of Physiology. Cell Physiology*. 2006; 290: C661–C668. <https://doi.org/10.1152/ajpcell.00459.2005>.

[129] Shimokawa H, Rashid M. Development of Rho-kinase inhibitors for cardiovascular medicine. *Trends in Pharmacological Sciences*. 2007; 28: 296–302. <https://doi.org/10.1016/j.tips.2007.04.006>.

[130] Shimokawa H, Sunamura S, Satoh K. RhoA/Rho-Kinase in the Cardiovascular System. *Circulation Research*. 2016; 118: 352–366. <https://doi.org/10.1161/CIRCRESAHA.115.306532>.

[131] Sanz-Moreno V, Gaggioli C, Yeo M, Albrengues J, Wallberg F, Viros A, *et al.* ROCK and JAK1 signaling cooperate to control actomyosin contractility in tumor cells and stroma. *Cancer Cell*. 2011; 20: 229–245. <https://doi.org/10.1016/j.ccr.2011.06.018>.

[132] Verdier V, Guang-Chao-Chen, Settleman J. Rho-kinase regulates tissue morphogenesis via non-muscle myosin and LIM-kinase during *Drosophila* development. *BMC Developmental Biology*. 2006; 6: 38. <https://doi.org/10.1186/1471-213X-6-38>.

[133] Benink HA, Bement WM. Concentric zones of active RhoA and Cdc42 around single cell wounds. *The Journal of Cell Biology*. 2005; 168: 429–439. <https://doi.org/10.1083/jcb.200411109>.

[134] Kamao H, Miki A, Kiryu J. ROCK Inhibitor-Induced Promotion of Retinal Pigment Epithelial Cell Motility during Wound Healing. *Journal of Ophthalmology*. 2019; 2019: 9428738. <https://doi.org/10.1155/2019/9428738>.

[135] Yin J, Yu FSX. Rho kinases regulate corneal epithelial wound healing. *American Journal of Physiology. Cell Physiology*. 2008; 295: C378–C387. <https://doi.org/10.1152/ajpcell.90624.2007>.

[136] Martino F, Perestrelo AR, Vinarský V, Pagliari S, Forte G. Cellular Mechanotransduction: From Tension to Function. *Frontiers in Physiology*. 2018; 9: 824. <https://doi.org/10.3389/fphys.2018.00824>.

[137] Stamenović D, Wang N. Stress transmission within the cell. *Comprehensive Physiology*. 2011; 1: 499–524. <https://doi.org/10.1002/cphy.c100019>.

[138] Di X, Gao X, Peng L, Ai J, Jin X, Qi S, et al. Cellular mechanotransduction in health and diseases: from molecular mechanism to therapeutic targets. *Signal Transduction and Targeted Therapy*. 2023; 8: 282. <https://doi.org/10.1038/s41392-023-01501-9>.

[139] Collins C, Tzima E. Rac[e] to the pole: setting up polarity in endothelial cells. *Small GTPases*. 2014; 5: 863–873. <https://doi.org/10.4161/sgtp.28650>.

[140] Liu Z, Tan JL, Cohen DM, Yang MT, Sniadecki NJ, Ruiz SA, et al. Mechanical tugging force regulates the size of cell-cell junctions. *Proceedings of the National Academy of Sciences of the United States of America*. 2010; 107: 9944–9949. <https://doi.org/10.1073/pnas.0914547107>.

[141] Burridge K, Monaghan-Benson E, Graham DM. Mechanotransduction: from the cell surface to the nucleus via RhoA. *Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences*. 2019; 374: 20180229. <https://doi.org/10.1098/rstb.2018.0229>.

[142] Asrani SG, McGlumphy EJ, Al-Aswad LA, Chaya CJ, Lin S, Musch DC, et al. The relationship between intraocular pressure and glaucoma: An evolving concept. *Progress in Retinal and Eye Research*. 2024; 103: 101303. <https://doi.org/10.1016/j.preteyes.2024.101303>.

[143] Jayaram H, Kolko M, Friedman DS, Gazzard G. Glaucoma: now and beyond. *Lancet (London, England)*. 2023; 402: 1788–1801. [https://doi.org/10.1016/S0140-6736\(23\)01289-8](https://doi.org/10.1016/S0140-6736(23)01289-8).

[144] Rao PV, Pattabiraman PP, Kopczynski C. Role of the Rho GTPase/Rho kinase signaling pathway in pathogenesis and treatment of glaucoma: Bench to bedside research. *Experimental Eye Research*. 2017; 158: 23–32. <https://doi.org/10.1016/j.exer.2016.08.023>.

[145] Kaufman PL. Deconstructing aqueous humor outflow - The last 50 years. *Experimental Eye Research*. 2020; 197: 108105. <https://doi.org/10.1016/j.exer.2020.108105>.

[146] Swaminathan SS, Oh DJ, Kang MH, Rhee DJ. Aqueous outflow: segmental and distal flow. *Journal of Cataract and Refractive Surgery*. 2014; 40: 1263–1272. <https://doi.org/10.1016/j.jcrs.2014.06.020>.

[147] Goel M, Picciani RG, Lee RK, Bhattacharya SK. Aqueous humor dynamics: a review. *The Open Ophthalmology Journal*. 2010; 4: 52–59. <https://doi.org/10.2174/1874364101004010052>.

[148] Johnson M, McLaren JW, Overby DR. Unconventional aqueous humor outflow: A review. *Experimental Eye Research*. 2017; 158: 94–111. <https://doi.org/10.1016/j.exer.2016.01.017>.

[149] Alward WLM. Biomedicine. A new angle on ocular development. *Science (New York, N.Y.)*. 2003; 299: 1527–1528. <https://doi.org/10.1126/science.1082933>.

[150] Keller KE, Acott TS. The Juxtaganular Region of Ocular Trabecular Meshwork: A Tissue with a Unique Extracellular Matrix and Specialized Function. *Journal of Ocular Biology*. 2013; 1: 3.

[151] Weinreb RN, Leung CKS, Crowston JG, Medeiros FA, Friedman DS, Wiggs JL, et al. Primary open-angle glaucoma. *Nature Reviews. Disease Primers*. 2016; 2: 16067. <https://doi.org/10.1038/nrdp.2016.67>.

[152] Sharif NA. Therapeutic Drugs and Devices for Tackling Ocular Hypertension and Glaucoma, and Need for Neuroprotection and Cytoprotective Therapies. *Frontiers in Pharmacology*. 2021; 12: 729249. <https://doi.org/10.3389/fphar.2021.729249>.

[153] Wiederholt M, Sturm A, Lepple-Wienhues A. Relaxation of trabecular meshwork and ciliary muscle by release of nitric oxide. *Investigative Ophthalmology & Visual Science*. 1994; 35: 2515–2520.

[154] Lepple-Wienhues A, Stahl F, Willner U, Schäfer R, Wiederholt M. Endothelin-evoked contractions in bovine ciliary muscle and trabecular meshwork: interaction with calcium, nifedipine and nickel. *Current Eye Research*. 1991; 10: 983–989. <https://doi.org/10.3109/02713689109020335>.

[155] Lepple-Wienhues A, Stahl F, Wiederholt M. Differential smooth muscle-like contractile properties of trabecular meshwork and ciliary muscle. *Experimental Eye Research*. 1991; 53: 33–38. [https://doi.org/10.1016/0014-4835\(91\)90141-z](https://doi.org/10.1016/0014-4835(91)90141-z).

[156] Pattabiraman PP, Rinkoski T, Poeschla E, Proia A, Challa P, Rao PV. RhoA GTPase-induced ocular hypertension in a rodent model is associated with increased fibrogenic activity in the trabecular meshwork. *The American Journal of Pathology*. 2015; 185: 496–512. <https://doi.org/10.1016/j.ajpath.2014.10.023>.

[157] Pattabiraman PP, Rao PV. Mechanistic Understanding of Rho GTPase-Induced Extracellular Matrix Synthesis and Organization in the Trabecular Meshwork Cells. *Investigative Ophthalmology & Visual Science*. 2009; 50: 4868.

[158] Pattabiraman PP, Inoue T, Rao PV. Elevated intraocular pressure induces Rho GTPase mediated contractile signaling in the trabecular meshwork. *Experimental Eye Research*. 2015; 136: 29–33. <https://doi.org/10.1016/j.exer.2015.05.001>.

[159] Haga RB, Ridley AJ. Rho GTPases: Regulation and roles in cancer cell biology. *Small GTPases*. 2016; 7: 207–221. <https://doi.org/10.1080/21541248.2016.1232583>.

[160] Hall A. Rho GTPases and the actin cytoskeleton. *Science (New York, N.Y.)*. 1998; 279: 509–514. <https://doi.org/10.1126/science.279.5350.509>.

[161] Ridley AJ. Rho family proteins: coordinating cell responses. *Trends in Cell Biology*. 2001; 11: 471–477. [https://doi.org/10.1016/s0962-8924\(01\)02153-5](https://doi.org/10.1016/s0962-8924(01)02153-5).

[162] Mettu PS, Deng PF, Misra UK, Gawdi G, Epstein DL, Rao PV. Role of lysophospholipid growth factors in the modulation of aqueous humor outflow facility. *Investigative Ophthalmology & Visual Science*. 2004; 45: 2263–2271. <https://doi.org/10.1167/iovs.03-0960>.

[163] Rao PV, Deng P, Sasaki Y, Epstein DL. Regulation of myosin light chain phosphorylation in the trabecular meshwork: role in aqueous humour outflow facility. *Experimental Eye Research*. 2005; 80: 197–206. <https://doi.org/10.1016/j.exer.2004.08.029>.

[164] Pattabiraman PP, Maddala R, Rao PV. Regulation of plasticity and fibrogenic activity of trabecular meshwork cells by Rho GTPase signaling. *Journal of Cellular Physiology*. 2014; 229: 927–942. <https://doi.org/10.1002/jcp.24524>.

[165] Pattabiraman PP, Rao PV. Mechanistic basis of Rho GTPase-induced extracellular matrix synthesis in trabecular meshwork

cells. *American Journal of Physiology. Cell Physiology*. 2010; 298: C749–63. <https://doi.org/10.1152/ajpcell.00317.2009>.

[166] Fillia MS, Schwinn MK, Sheibani N, Kaufman PL, Peters DM. Regulation of cross-linked actin network (CLAN) formation in human trabecular meshwork (HTM) cells by convergence of distinct beta1 and beta3 integrin pathways. *Investigative Ophthalmology & Visual Science*. 2009; 50: 5723–5731. <https://doi.org/10.1167/iovs.08-3215>.

[167] Fillia MS, Clark R, Peters DM. A syndecan-4 binding peptide derived from laminin 5 uses a novel PKC ϵ pathway to induce cross-linked actin network (CLAN) formation in human trabecular meshwork (HTM) cells. *Experimental Cell Research*. 2014; 327: 171–182. <https://doi.org/10.1016/j.yexcr.2014.07.035>.

[168] Clark AF, Brotchie D, Read AT, Hellberg P, English-Wright S, Pang IH, et al. Dexamethasone alters F-actin architecture and promotes cross-linked actin network formation in human trabecular meshwork tissue. *Cell Motility and the Cytoskeleton*. 2005; 60: 83–95. <https://doi.org/10.1002/cm.20049>.

[169] Buffault J, Brignole-Baudouin F, Reboussin É, Kessal K, Labb   A, M  lik Parsadaniantz S, et al. The Dual Effect of Rho-Kinase Inhibition on Trabecular Meshwork Cells Cytoskeleton and Extracellular Matrix in an In Vitro Model of Glaucoma. *Journal of Clinical Medicine*. 2022; 11: 1001. <https://doi.org/10.3390/jcm11041001>.

[170] Montecchi-Palmer M, Bermudez JY, Webber HC, Patel GC, Clark AF, Mao W. TGF β 2 Induces the Formation of Cross-Linked Actin Networks (CLANs) in Human Trabecular Meshwork Cells Through the Smad and Non-Smad Dependent Pathways. *Investigative Ophthalmology & Visual Science*. 2017; 58: 1288–1295. <https://doi.org/10.1167/iovs.16-19672>.

[171] Li H, Henty-Ridilla JL, Bernstein AM, Ganapathy PS, Herberg S. TGF β 2 Regulates Human Trabecular Meshwork Cell Contractility via ERK and ROCK Pathways with Distinct Signaling Crosstalk Dependent on the Culture Substrate. *Current Eye Research*. 2022; 47: 1165–1178. <https://doi.org/10.1080/02713683.2022.2071943>.

[172] Rudzitis CN, Lakk M, Singh A, Redmon SN, Kirdajov   D, Tseng YT, et al. TRPV4 activation by TGF β 2 enhances cellular contractility and drives ocular hypertension. *eLife*. 2025; 14: RP104894. <https://doi.org/10.7554/eLife.104894>.

[173] Liu HW, Halayko AJ, Fernandes DJ, Harmon GS, McCauley JA, Kocieniewski P, et al. The RhoA/Rho kinase pathway regulates nuclear localization of serum response factor. *American Journal of Respiratory Cell and Molecular Biology*. 2003; 29: 39–47. <https://doi.org/10.1165/rccm.2002-0206OC>.

[174] Chihara K, Amano M, Nakamura N, Yano T, Shibata M, Tokui T, et al. Cytoskeletal rearrangements and transcriptional activation of c-fos serum response element by Rho-kinase. *The Journal of Biological Chemistry*. 1997; 272: 25121–25127. <https://doi.org/10.1074/jbc.272.40.25121>.

[175] Yu-Wai-Man C, Treisman R, Baily M, Khaw PT. The role of the MRTF-A/SRF pathway in ocular fibrosis. *Investigative Ophthalmology & Visual Science*. 2014; 55: 4560–4567. <https://doi.org/10.1167/iovs.14-14692>.

[176] Hsu CC, Lin FP, Tseng HC, Ho PK, Chen YH, Chen YG, et al. Activation of the ROCK/MYLK Pathway Affects Complex Molecular and Morphological Changes of the Trabecular Meshwork Associated With Ocular Hypertension. *Investigative Ophthalmology & Visual Science*. 2024; 65: 17. <https://doi.org/10.1167/iovs.65.10.17>.

[177] Wiggs JL, Pasquale LR. Genetics of glaucoma. *Human Molecular Genetics*. 2017; 26: R21–R27. <https://doi.org/10.1093/hmg/dds184>.

[178] Springelkamp H, Iglesias AI, Cuellar-Partida G, Amin N, Burdon KP, van Leeuwen EM, et al. ARHGEF12 influences the risk of glaucoma by increasing intraocular pressure. *Human Molecular Genetics*. 2015; 24: 2689–2699. <https://doi.org/10.1093/hmg/dds027>.

[179] Goldhagen B, Proia AD, Epstein DL, Rao PV. Elevated levels of RhoA in the optic nerve head of human eyes with glaucoma. *Journal of Glaucoma*. 2012; 21: 530–538. <https://doi.org/10.1097/JG.0b013e318241b83c>.

[180] Lukas TJ, Miao H, Chen L, Riordan SM, Li W, Crabb AM, et al. Susceptibility to glaucoma: differential comparison of the astrocyte transcriptome from glaucomatous African American and Caucasian American donors. *Genome Biology*. 2008; 9: R111. <https://doi.org/10.1186/gb-2008-9-7-r111>.

[181] Kompass KS, Agapova OA, Li W, Kaufman PL, Rasmussen CA, Hernandez MR. Bioinformatic and statistical analysis of the optic nerve head in a primate model of ocular hypertension. *BMC Neuroscience*. 2008; 9: 93. <https://doi.org/10.1186/1471-2202-9-93>.

[182] Kim JW. Comparative Study of the Effects of Trabecular Meshwork Outflow Drugs on the Permeability and Nitric Oxide Production in Trabecular Meshwork Cells. *Korean Journal of Ophthalmology: KJO*. 2017; 31: 452–459. <https://doi.org/10.3341/kjo.2017.0020>.

[183] Koga T, Koga T, Awai M, Tsutsui JI, Yue BYJT, Tanihara H. Rho-associated protein kinase inhibitor, Y-27632, induces alterations in adhesion, contraction and motility in cultured human trabecular meshwork cells. *Experimental Eye Research*. 2006; 82: 362–370. <https://doi.org/10.1016/j.exer.2005.07.006>.

[184] Honjo M, Tanihara H, Inatani M, Kido N, Sawamura T, Yue BY, et al. Effects of rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility. *Investigative Ophthalmology & Visual Science*. 2001; 42: 137–144.

[185] Thieme H, Stumpff F, Ottlecz A, Percicot CL, Lambrou GN, Wiederholt M. Mechanisms of action of unoprostone on trabecular meshwork contractility. *Investigative Ophthalmology & Visual Science*. 2001; 42: 3193–3201.

[186] Rao VP, Epstein DL. Rho GTPase/Rho kinase inhibition as a novel target for the treatment of glaucoma. *Bio-Drugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy*. 2007; 21: 167–177. <https://doi.org/10.2165/00063030-200721030-00004>.

[187] Rao PV, Deng PF, Kumar J, Epstein DL. Modulation of aqueous humor outflow facility by the Rho kinase-specific inhibitor Y-27632. *Investigative Ophthalmology & Visual Science*. 2001; 42: 1029–1037.

[188] Bonardi A, Supuran CT. Treatment of glaucoma and ocular hypertension using rho kinase inhibitors: patent evaluation of US2018244666 and US2018256595. *Expert Opinion on Therapeutic Patents*. 2019; 29: 753–759. <https://doi.org/10.1080/13543776.2019.1658743>.

[189] Ashwinbalaji S, Haribalaganesh R, Krishnadas S, Muthukkaruppan V, Senthilkumari S. SB772077B (SB77) Alleviated the Aqueous Outflow Resistance Mediated by Cyclic Mechanical Stress in Perfused Human Cadaveric Eyes. *Scientific Reports*. 2020; 10: 10202. <https://doi.org/10.1038/s41598-020-67087-2>.

[190] Ashwinbalaji S, Senthilkumari S, Gowripriy C, Krishnadas S, Gabelt BAT, Kaufman PL, et al. SB772077B, A New Rho Kinase Inhibitor Enhances Aqueous Humour Outflow Facility in Human Eyes. *Scientific Reports*. 2018; 8: 15472. <https://doi.org/10.1038/s41598-018-33932-8>.

[191] Juneja R, Khan T, Gupta VS, Chaudhary N. Netarsudil v/s Rimasudil: The battle of supremacy between two ROCKS-I (rho kinase inhibitors). *International Ophthalmology*. 2025; 45: 240. <https://doi.org/10.1007/s10792-025-03590-7>.

[192] Li Q, Li C, Chang Y, Su M, Yu R, Huang Z, et al. Design, Synthesis, and Evaluation of Novel ROCK Inhibitors for Glaucoma Treatment: Insights into In Vitro and In Vivo Efficacy

and Safety. *Journal of Medicinal Chemistry*. 2025; 68: 10008–10030. <https://doi.org/10.1021/acs.jmedchem.4c03047>.

[193] Stalmans I, Lim KS, Oddone F, Fichtl M, Belda JI, Hommer A, *et al.* MERCURY-3: a randomized comparison of netarsudil/latanoprost and bimatoprost/timolol in open-angle glaucoma and ocular hypertension. *Graefes Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie*. 2024; 262: 179–190. <https://doi.org/10.1007/s00417-023-06192-0>.

[194] Konda SM, Kaufman PL. New Therapies to Reduce Intraocular Pressures. *Journal of Ocular Pharmacology and Therapeutics: the Official Journal of the Association for Ocular Pharmacology and Therapeutics*. 2019; 35: 322–324. <https://doi.org/10.1089/jop.2019.0059>.

[195] Tian B, Geiger B, Epstein DL, Kaufman PL. Cytoskeletal involvement in the regulation of aqueous humor outflow. *Investigative Ophthalmology & Visual Science*. 2000; 41: 619–623.

[196] Torrejon KY, Papke EL, Halman JR, Bergkvist M, Danias J, Sharfstein ST, *et al.* TGF β 2-induced outflow alterations in a bio-engineered trabecular meshwork are offset by a rho-associated kinase inhibitor. *Scientific Reports*. 2016; 6: 38319. <https://doi.org/10.1038/srep38319>.

[197] Fujimoto T, Inoue-Mochita M, Inoue T. A ROCK inhibitor suppresses the transforming growth factor-beta-2-induced endothelial-mesenchymal transition in Schlemm's canal endothelial cells. *Scientific Reports*. 2023; 13: 9655. <https://doi.org/10.1038/s41598-023-36808-8>.

[198] Katoh K, Kano Y, Amano M, Kaibuchi K, Fujiwara K. Stress fiber organization regulated by MLCK and Rho-kinase in cultured human fibroblasts. *American Journal of Physiology. Cell Physiology*. 2001; 280: C1669–C1679. <https://doi.org/10.1152/ajpcell.2001.280.6.C1669>.

[199] Yamagishi-Kimura R, Honjo M, Aihara M. Neuroprotective effect of ripasudil on retinal ganglion cells via an antioxidant mechanism. *Japanese Journal of Ophthalmology*. 2025; 69: 823–832. <https://doi.org/10.1007/s10384-025-01243-x>.

[200] Sakurai K, Suda K, Akagi T, Ikeda HO, Kameda T, Miyake M, *et al.* Effect of Ripasudil on the Change Rates of the Circumpapillary Retinal Nerve Fiber Layer Thickness in Patients With Primary Open-Angle Glaucoma. *Journal of Ophthalmology*. 2025; 2025: 2962982. <https://doi.org/10.1155/joph/2962982>.

[201] Quillen SE, Kimball EC, Ritter-Gordy KA, Du L, Yuan Z, Pease ME, *et al.* The Mechanisms of Neuroprotection by Topical Rho Kinase Inhibition in Experimental Mouse Glaucoma and Optic Neuropathy. *Investigative Ophthalmology & Visual Science*. 2024; 65: 43. <https://doi.org/10.1167/iovs.65.13.43>.

[202] Lo J, Mehta K, Dhillon A, Huang YK, Luo Z, Nam MH, *et al.* Therapeutic strategies for glaucoma and optic neuropathies. *Molecular Aspects of Medicine*. 2023; 94: 101219. <https://doi.org/10.1016/j.mam.2023.101219>.

[203] Guilluy C, Garcia-Mata R, Burridge K. Rho protein crosstalk: another social network? *Trends in Cell Biology*. 2011; 21: 718–726. <https://doi.org/10.1016/j.tcb.2011.08.002>.

[204] Kutys ML, Yamada KM. Rho GEFs and GAPs: emerging integrators of extracellular matrix signaling. *Small GTPases*. 2015; 6: 16–19. <https://doi.org/10.4161/21541248.2014.989792>.

[205] Nguyen LK, Kholodenko BN, von Kriegsheim A. Rac1 and RhoA: Networks, loops and bistability. *Small GTPases*. 2018; 9: 316–321. <https://doi.org/10.1080/21541248.2016.1224399>.

[206] Martin E, Ouellette MH, Jenna S. Rac1/RhoA antagonism defines cell-to-cell heterogeneity during epidermal morphogenesis in nematodes. *The Journal of Cell Biology*. 2016; 215: 483–498. <https://doi.org/10.1083/jcb.201604015>.

[207] Christopherson C. Comparative Optic Nerve Head Physiology: Glaucoma Induced Retinal Ganglion Cell Apoptosis by Disruption of the Translaminar Pressure Gradient and Reduced Neurotrophic Signaling. South Dakota State University: South Dakota (SD). 2019.

[208] Castellano E, Downward J. RAS Interaction with PI3K: More Than Just Another Effector Pathway. *Genes & Cancer*. 2011; 2: 261–274. <https://doi.org/10.1177/1947601911408079>.

[209] Fritsch R, de Krijger I, Fritsch K, George R, Reason B, Kumar MS, *et al.* RAS and RHO families of GTPases directly regulate distinct phosphoinositide 3-kinase isoforms. *Cell*. 2013; 153: 1050–1063. <https://doi.org/10.1016/j.cell.2013.04.031>.

[210] Soundararajan A, Wang T, Sundararajan R, Wijeratne A, Mosley A, Harvey FC, *et al.* Multiomics analysis reveals the mechanical stress-dependent changes in trabecular meshwork cytoskeletal-extracellular matrix interactions. *Frontiers in Cell and Developmental Biology*. 2022; 10: 874828. <https://doi.org/10.3389/fcell.2022.874828>.

[211] Soriano O, Alcón-Pérez M, Vicente-Manzanares M, Castellano E. The Crossroads between RAS and RHO Signaling Pathways in Cellular Transformation, Motility and Contraction. *Genes*. 2021; 12: 819. <https://doi.org/10.3390/genes12060819>.

[212] Tong J, Li L, Ballermann B, Wang Z. Phosphorylation and Activation of RhoA by ERK in Response to Epidermal Growth Factor Stimulation. *PloS One*. 2016; 11: e0147103. <https://doi.org/10.1371/journal.pone.0147103>.

[213] Han JS, Macarak E, Rosenblom J, Chung KC, Chaqour B. Regulation of Cyr61/CCN1 gene expression through RhoA GTPase and p38MAPK signaling pathways. *European Journal of Biochemistry*. 2003; 270: 3408–3421. <https://doi.org/10.1046/j.1432-1033.2003.03723.x>.

[214] Zohrabian VM, Forzani B, Chau Z, Murali R, Jhanwar-Uniyal M. Rho/ROCK and MAPK signaling pathways are involved in glioblastoma cell migration and proliferation. *Anticancer Research*. 2009; 29: 119–123.

[215] Shi J, Wei L. Rho kinase in the regulation of cell death and survival. *Archivum Immunologiae et Therapiae Experimentalis*. 2007; 55: 61–75. <https://doi.org/10.1007/s00005-007-0009-7>.

[216] Iwasaki K, Hayashi K, Fujioka T, Sobue K. Rho/Rho-associated kinase signal regulates myogenic differentiation via myocardin-related transcription factor-A/Smad-dependent transcription of the Id3 gene. *The Journal of Biological Chemistry*. 2008; 283: 21230–21241. <https://doi.org/10.1074/jbc.M710525200>.

[217] Gupta M, Korol A, West-Mays JA. Nuclear translocation of myocardin-related transcription factor-A during transforming growth factor beta-induced epithelial to mesenchymal transition of lens epithelial cells. *Molecular Vision*. 2013; 19: 1017–1028.

[218] McGee KM, Vartiainen MK, Khaw PT, Treisman R, Baily M. Nuclear transport of the serum response factor coactivator MRTF-A is downregulated at tensional homeostasis. *EMBO Reports*. 2011; 12: 963–970. <https://doi.org/10.1038/embor.2011.141>.

[219] Miralles F, Posern G, Zaromytidou AI, Treisman R. Actin dynamics control SRF activity by regulation of its coactivator MAL. *Cell*. 2003; 113: 329–342. [https://doi.org/10.1016/s0092-8674\(03\)00278-2](https://doi.org/10.1016/s0092-8674(03)00278-2).

[220] Geneste O, Copeland JW, Treisman R. LIM kinase and Diaphanous cooperate to regulate serum response factor and actin dynamics. *The Journal of Cell Biology*. 2002; 157: 831–838. <https://doi.org/10.1083/jcb.200203126>.

[221] Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT. The PI3K Pathway in Human Disease. *Cell*. 2017; 170: 605–635. <https://doi.org/10.1016/j.cell.2017.07.029>.

[222] Street CA, Bryan BA. Rho kinase proteins—pleiotropic modulators of cell survival and apoptosis. *Anticancer Research*. 2011; 31: 3645–3657.

[223] Maruhashi T, Noma K, Iwamoto Y, Iwamoto A, Oda N, Kajikawa M, *et al.* Critical role of exogenous nitric oxide in ROCK

activity in vascular smooth muscle cells. *PLoS One*. 2014; 9: e109017. <https://doi.org/10.1371/journal.pone.0109017>.

[224] Nour-Eldine W, Ghantous CM, Zibara K, Dib L, Issaa H, Itani HA, *et al.* Adiponectin Attenuates Angiotensin II-Induced Vascular Smooth Muscle Cell Remodeling through Nitric Oxide and the RhoA/ROCK Pathway. *Frontiers in Pharmacology*. 2016; 7: 86. <https://doi.org/10.3389/fphar.2016.00086>.

[225] Cuesta C, Arévalo-Alameda C, Castellano E. The Importance of Being PI3K in the RAS Signaling Network. *Genes*. 2021; 12: 1094. <https://doi.org/10.3390/genes12071094>.

[226] He Y, Sun MM, Zhang GG, Yang J, Chen KS, Xu WW, *et al.* Targeting PI3K/Akt signal transduction for cancer therapy. *Signal Transduction and Targeted Therapy*. 2021; 6: 425. <https://doi.org/10.1038/s41392-021-00828-5>.

[227] Alfieri R, Giovannetti E, Bonelli M, Cavazzoni A. New Treatment Opportunities in Phosphatase and Tensin Homolog (PTEN)-Deficient Tumors: Focus on PTEN/Focal Adhesion Kinase Pathway. *Frontiers in Oncology*. 2017; 7: 170. <https://doi.org/10.3389/fonc.2017.00170>.

[228] Liu L, Wang Y, Yu Q. The PI3K/Akt signaling pathway exerts effects on the implantation of mouse embryos by regulating the expression of RhoA. *International Journal of Molecular Medicine*. 2014; 33: 1089–1096. <https://doi.org/10.3892/ijmm.2014.1701>.

[229] Sun W, Yang J. Molecular basis of lysophosphatidic acid-induced NF- κ B activation. *Cellular Signalling*. 2010; 22: 1799–1803. <https://doi.org/10.1016/j.cellsig.2010.05.007>.

[230] Bradbury EJ, Burnside ER. Moving beyond the glial scar for spinal cord repair. *Nature Communications*. 2019; 10: 3879. <https://doi.org/10.1038/s41467-019-11707-7>.

[231] Tian B, Gabelt BT, Peterson JA, Kiland JA, Kaufman PL. H-7 increases trabecular facility and facility after ciliary muscle disinsertion in monkeys. *Investigative Ophthalmology & Visual Science*. 1999; 40: 239–242.

[232] Lin CW, Sherman B, Moore LA, Laethem CL, Lu DW, Pattabiraman PP, *et al.* Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma. *Journal of Ocular Pharmacology and Therapeutics: the Official Journal of the Association for Ocular Pharmacology and Therapeutics*. 2018; 34: 40–51. <https://doi.org/10.1089/jop.2017.0023>.

[233] Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Suganami H, *et al.* Additive Intraocular Pressure-Lowering Effects of the Rho Kinase Inhibitor Ripasudil (K-115) Combined With Timolol or Latanoprost: A Report of 2 Randomized Clinical Trials. *JAMA Ophthalmology*. 2015; 133: 755–761. <https://doi.org/10.1001/jamaophthalmol.2015.0525>.

[234] Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Suganami H, *et al.* Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study. *Acta Ophthalmologica*. 2015; 93: e254–e260. <https://doi.org/10.1111/aoe.12599>.

[235] Kaneko Y, Ohta M, Inoue T, Mizuno K, Isobe T, Tanabe S, *et al.* Effects of K-115 (Ripasudil), a novel ROCK inhibitor, on trabecular meshwork and Schlemm's canal endothelial cells. *Scientific Reports*. 2016; 6: 19640. <https://doi.org/10.1038/srep19640>.

[236] Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Fukushima A, *et al.* One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension. *Acta Ophthalmologica*. 2016; 94: e26–e34. <https://doi.org/10.1111/aoe.12829>.

[237] Lewis RA, Levy B, Ramirez N, Kopczynski CC, Usner DW, Novack GD, *et al.* Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension. *The British Journal of Ophthalmology*. 2016; 100: 339–344. <https://doi.org/10.1136/bjophthalmol-2015-306778>.

[238] Wang RF, Williamson JE, Kopczynski C, Serle JB. Effect of 0.04% AR-13324, a ROCK, and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyes. *Journal of Glaucoma*. 2015; 24: 51–54. <https://doi.org/10.1097/JG.0b013e3182952213>.

[239] Kiel JW, Kopczynski CC. Effect of AR-13324 on episcleral venous pressure in Dutch belted rabbits. *Journal of Ocular Pharmacology and Therapeutics: the Official Journal of the Association for Ocular Pharmacology and Therapeutics*. 2015; 31: 146–151. <https://doi.org/10.1089/jop.2014.0146>.

[240] Bacharach J, Dubiner HB, Levy B, Kopczynski CC, Novack GD, AR-13324-CS202 Study Group. Double-masked, randomized, dose-response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure. *Ophthalmology*. 2015; 122: 302–307. <https://doi.org/10.1016/j.ophtha.2014.08.022>.

[241] Kopczynski CC, Heah T. Netarsudil ophthalmic solution 0.02% for the treatment of patients with open-angle glaucoma or ocular hypertension. *Drugs of Today (Barcelona, Spain)*. 1998. 2018; 54: 467–478. <https://doi.org/10.1358/dot.2018.54.8.2849627>.

[242] Kazemi A, McLaren JW, Kopczynski CC, Heah TG, Novack GD, Sit AJ. The Effects of Netarsudil Ophthalmic Solution on Aqueous Humor Dynamics in a Randomized Study in Humans. *Journal of Ocular Pharmacology and Therapeutics: the Official Journal of the Association for Ocular Pharmacology and Therapeutics*. 2018; 34: 380–386. <https://doi.org/10.1089/jop.2017.0138>.

[243] Wang J, Wang H, Dang Y. Rho-Kinase Inhibitors as Emerging Targets for Glaucoma Therapy. *Ophthalmology and Therapy*. 2023; 12: 2943–2957. <https://doi.org/10.1007/s40123-023-00820-y>.

[244] Wu J, Wei J, Chen H, Dang Y, Lei F. Rho Kinase (ROCK) Inhibitors for the Treatment of Glaucoma. *Current Drug Targets*. 2024; 25: 94–107. <https://doi.org/10.2174/0113894501286195231220094646>.

[245] Kopczynski C, Novack GD, Swearingen D, van Haarlem T. Ocular hypotensive efficacy, safety and systemic absorption of AR-12286 ophthalmic solution in normal volunteers. *The British Journal of Ophthalmology*. 2013; 97: 567–572. <https://doi.org/10.1136/bjophthalmol-2012-302466>.

[246] Inoue T, Tanihara H. Rho-associated kinase inhibitors: a novel glaucoma therapy. *Progress in Retinal and Eye Research*. 2013; 37: 1–12. <https://doi.org/10.1016/j.preteyeres.2013.05.002>.

[247] Lee AJ, Goldberg I. Emerging drugs for ocular hypertension. *Expert Opinion on Emerging Drugs*. 2011; 16: 137–161. <https://doi.org/10.1517/14728214.2011.521631>.

[248] Van de Velde S, Van Bergen T, Sijnave D, Hollanders K, Castermans K, Defert O, *et al.* AMA0076, a novel, locally acting Rho kinase inhibitor, potently lowers intraocular pressure in New Zealand white rabbits with minimal hyperemia. *Investigative Ophthalmology & Visual Science*. 2014; 55: 1006–1016. <https://doi.org/10.1167/iovs.13-13157>.

[249] Karimi A, Aga M, Stanik A, Harbaugh T, Coffey E, White E, *et al.* 3D traction force microscopy in human trabecular meshwork tissues: Effects of ROCK and YAP/TAZ inhibition in normal and glaucomatous tissues. *Tissue & Cell*. 2025; 96: 103005. <https://doi.org/10.1016/j.tice.2025.103005>.

[250] Karimi A, Aga M, Khan T, D'costa SD, Cardenas-Riumallo S, Zelenitz M, *et al.* Dynamic traction force in trabecular meshwork cells: A 2D culture model for normal and glaucomatous states. *Acta Biomaterialia*. 2024; 175: 138–156. <https://doi.org/10.1016/j.actbio.2023.12.033>.

[251] Sit AJ, Aihara M, Khawaja AP, Lin SC, Mansouri K, Miki A, *et al.* Clinical implications of lowering episcleral venous pres-

sure in the management of glaucoma and the use of Rho kinase inhibitors. *Survey of Ophthalmology*. 2025; 70: 918–929. <https://doi.org/10.1016/j.survophthal.2025.03.003>.

[252] Sinha S, Lee D, Kolomeyer NN, Myers JS, Razeghinejad R. Fixed combination netarsudil-latanoprost for the treatment of glaucoma and ocular hypertension. *Expert Opinion on Pharmacotherapy*. 2020; 21: 39–45. <https://doi.org/10.1080/14656566.2019.1685499>.

[253] Tanihara H, Kakuda T, Sano T, Kanno T, Kurihara Y. Long-Term Intraocular Pressure-Lowering Effects and Adverse Events of Ripasudil in Patients with Glaucoma or Ocular Hypertension over 24 Months. *Advances in Therapy*. 2022; 39: 1659–1677. <https://doi.org/10.1007/s12325-021-02023-y>.

[254] Abbhi V, Piplani P. Rho-kinase (ROCK) Inhibitors - A Neuroprotective Therapeutic Paradigm with a Focus on Ocular Utility. *Current Medicinal Chemistry*. 2020; 27: 2222–2256. <https://doi.org/10.2174/092986732566181031102829>.

[255] Shaw PX, Sang A, Wang Y, Ho D, Douglas C, Dia L, *et al.* Topical administration of a Rock/Net inhibitor promotes retinal ganglion cell survival and axon regeneration after optic nerve injury. *Experimental Eye Research*. 2017; 158: 33–42. <https://doi.org/10.1016/j.exer.2016.07.006>.

[256] Levy B, Ramirez N, Novack GD, Kopczynski C. Ocular hypotensive safety and systemic absorption of AR-13324 ophthalmic solution in normal volunteers. *American Journal of Ophthalmology*. 2015; 159: 980–5.e1. <https://doi.org/10.1016/j.ajo.2015.01.026>.

[257] Hoy SM. Netarsudil Ophthalmic Solution 0.02%: First Global Approval. *Drugs*. 2018; 78: 389–396. <https://doi.org/10.1007/s40265-018-0877-7>.

[258] Mehran NA, Sinha S, Razeghinejad R. New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost. *Eye (London, England)*. 2020; 34: 72–88. <https://doi.org/10.1038/s41433-019-0671-0>.

[259] Asrani S, Bacharach J, Holland E, McKee H, Sheng H, Lewis RA, *et al.* Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2. *Advances in Therapy*. 2020; 37: 1620–1631. <https://doi.org/10.1007/s12325-020-01277-2>.

[260] Radell JE, Serle JB. Netarsudil/latanoprost fixed-dose combination for the treatment of open-angle glaucoma or ocular hypertension. *Drugs of Today (Barcelona, Spain: 1998)*. 2019; 55: 563–574. <https://doi.org/10.1358/dot.2019.55.9.3039670>.

[261] Clement Freiberg J, von Spreckelsen A, Kolko M, Azuara-Blanco A, Virgili G. Rho kinase inhibitor for primary open-angle glaucoma and ocular hypertension. *The Cochrane Database of Systematic Reviews*. 2022; 6: CD013817. <https://doi.org/10.1002/14651858.CD013817.pub2>.

[262] Rivera SS, Radunzel N, Boese EA. Symptomatic Netarsudil-Induced Verticillata. *JAMA Ophthalmology*. 2023; 141: e232949. <https://doi.org/10.1001/jamaophthalmol.2023.2949>.

[263] Holló G. Ocular hyperemia associated with topical glaucoma medication: understanding and differentiating clinical appearance and underlying mechanisms. *Expert Opinion on Drug Safety*. 2025; 24: 145–156. <https://doi.org/10.1080/14740338.2024.2436062>.

[264] Chu MJ, Song M, Palmares T, Song A, Song J. Rhopressa-induced corneal edema: a case report. *Journal of Medical Case Reports*. 2021; 15: 182. <https://doi.org/10.1186/s13256-021-02665-0>.

[265] Sahyoun JY, Sabeti S, Robert MC. Drug-induced corneal deposits: an up-to-date review. *BMJ Open Ophthalmology*. 2022; 7: e000943. <https://doi.org/10.1136/bmjophth-2021-000943>.

[266] Tanna AP, Johnson M. Rho Kinase Inhibitors as a Novel Treatment for Glaucoma and Ocular Hypertension. *Ophthalmology*. 2018; 125: 1741–1756. <https://doi.org/10.1016/j.ophtha.2018.04.040>.

[267] Van de Velde S, De Groef L, Stalmans I, Moons L, Van Hove I. Towards axonal regeneration and neuroprotection in glaucoma: Rho kinase inhibitors as promising therapeutics. *Progress in Neurobiology*. 2015; 131: 105–119. <https://doi.org/10.1016/j.pneurobio.2015.06.002>.

[268] Wang LH, Huang CH, Lin IC. Advances in Neuroprotection in Glaucoma: Pharmacological Strategies and Emerging Technologies. *Pharmaceuticals (Basel, Switzerland)*. 2024; 17: 1261. <https://doi.org/10.3390/ph17101261>.

[269] Wong KA, Benowitz LI. Retinal Ganglion Cell Survival and Axon Regeneration after Optic Nerve Injury: Role of Inflammation and Other Factors. *International Journal of Molecular Sciences*. 2022; 23: 10179. <https://doi.org/10.3390/ijms231710179>.

[270] Ahmed Z, Suggate EL, Logan A, Berry M. Retinal Ganglion Cell Survival and Axon Regeneration after Optic Nerve Transection is Driven by Cellular Intravitreal Sciatic Nerve Grafts. *Cells*. 2020; 9: 1335. <https://doi.org/10.3390/cells9061335>.

[271] Moura-Coelho N, Tavares Ferreira J, Bruxelas CP, Dutra-Medeiros M, Cunha JP, Pinto Proença R. Rho kinase inhibitors—a review on the physiology and clinical use in Ophthalmology. *Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie*. 2019; 257: 1101–1117. <https://doi.org/10.1007/s00417-019-04283-5>.

[272] Dasso L, Al-Khaled T, Sonty S, Aref AA. Profile of netarsudil ophthalmic solution and its potential in the treatment of open-angle glaucoma: evidence to date. *Clinical Ophthalmology (Auckland, N.Z.)*. 2018; 12: 1939–1944. <https://doi.org/10.2147/OPHT.S154001>.

[273] Wu J, Li J, Hu H, Liu P, Fang Y, Wu D. Rho-kinase inhibitor, fasudil, prevents neuronal apoptosis via the Akt activation and PTEN inactivation in the ischemic penumbra of rat brain. *Cellular and Molecular Neurobiology*. 2012; 32: 1187–1197. <https://doi.org/10.1007/s10571-012-9845-z>.

[274] Wang X, Sun L, Han X, Li Z, Xing Y, Chen X, *et al.* The molecular mechanisms underlying retinal ganglion cell apoptosis and optic nerve regeneration in glaucoma (Review). *International Journal of Molecular Medicine*. 2025; 55: 63. <https://doi.org/10.3892/ijmm.2025.5504>.

[275] Singh K, Singh A. Rho-kinase Inhibitors in Ocular Diseases: A Translational Research Journey. *Journal of Current Glaucoma Practice*. 2023; 17: 44–48. <https://doi.org/10.5005/jp-journal-s-10078-1396>.

[276] Okumura N, Kinoshita S, Koizumi N. The Role of Rho Kinase Inhibitors in Corneal Endothelial Dysfunction. *Current Pharmaceutical Design*. 2017; 23: 660–666. <https://doi.org/10.2174/138161282266161205110027>.

[277] Tan JK, Steel DH, Ahmad S, Viswanathan A, Mathew RG, Khaw PT, *et al.* Exploring the potential of rho kinase inhibitors in ophthalmology: From mechanisms to clinical practice. *Survey of Ophthalmology*. 2025; 70: 900–917. <https://doi.org/10.1016/j.survophthal.2025.03.008>.

[278] Meekins LC, Rosado-Adames N, Maddala R, Zhao JJ, Rao PV, Afshari NA. Corneal Endothelial Cell Migration and Proliferation Enhanced by Rho Kinase (ROCK) Inhibitors in In Vitro and In Vivo Models. *Investigative Ophthalmology & Visual Science*. 2016; 57: 6731–6738. <https://doi.org/10.1167/iovs.16-20414>.

[279] Yamaguchi M, Nakao S, Arima M, Wada I, Kaizu Y, Hao F, *et al.* Rho-Kinase/ROCK as a Potential Drug Target for Vitreoretinal Diseases. *Journal of Ophthalmology*. 2017; 2017: 8543592. <https://doi.org/10.1155/2017/8543592>.

[280] Arita R, Hata Y, Ishibashi T. ROCK as a Therapeutic Target of Diabetic Retinopathy. *Journal of Ophthalmology*. 2010; 2010:

175163. <https://doi.org/10.1155/2010/175163>.

[281] Tang F, Huang K, Peng B, Deng W, Su N, Xu F, *et al.* RhoA/ROCK Signaling Is Involved in Pathological Retinal Neovascularization. *Journal of Vascular Research*. 2023; 60: 183–192. <https://doi.org/10.1159/000533321>.

[282] Reboussin É, Bastelica P, Benmessabih I, Cordovilla A, Delarasse C, Réaux-Le Goazigo A, *et al.* Evaluation of Rho kinase inhibitor effects on neuroprotection and neuroinflammation in an ex-vivo retinal explant model. *Acta Neuropathologica Communications*. 2024; 12: 150. <https://doi.org/10.1186/s40478-024-01859-z>.

[283] Li G, Lee C, Read AT, Wang K, Ha J, Kuhn M, *et al.* Anti-fibrotic activity of a rho-kinase inhibitor restores outflow function and intraocular pressure homeostasis. *eLife*. 2021; 10: e60831. <https://doi.org/10.7554/eLife.60831>.

[284] Halász É, Townes-Anderson E, Zarbin MA. Improving outcomes in retinal detachment: the potential role of rho-kinase inhibitors. *Current Opinion in Ophthalmology*. 2020; 31: 192–198. <https://doi.org/10.1097/ICU.0000000000000658>.

[285] Sanchez-Suarez JF, Arevalo-Alquichire S, Miller WP, Amarnani D, Barake KW, Semegran M, *et al.* Rho-kinase pathway inhibition for proliferative vitreoretinopathy: assessing the therapeutic potential of netarsudil. *Investigative Ophthalmology & Visual Science*. 2024; 65: 6060.

[286] Ramos L, Amarnani D, Singh N, Kim LA. Effect of Rho-kinase Inhibition on a Patient-Derived Model of Proliferative Vitreoretinopathy. *Investigative Ophthalmology & Visual Science*. 2021; 62: 3641.

[287] Labandeira-Garcia JL, Rodríguez-Perez AI, Villar-Cheda B, Borrajo A, Dominguez-Mejide A, Guerra MJ. Rho Kinase and Dopaminergic Degeneration: A Promising Therapeutic Target for Parkinson's Disease. *The Neuroscientist: a Review Journal Bringing Neurobiology, Neurology and Psychiatry*. 2015; 21: 616–629. <https://doi.org/10.1177/1073858414554954>.

[288] Gu QF, Yu JZ, Wu H, Li YH, Liu CY, Feng L, *et al.* Therapeutic effect of Rho kinase inhibitor FSD-C10 in a mouse model of Alzheimer's disease. *Experimental and Therapeutic Medicine*. 2018; 16: 3929–3938. <https://doi.org/10.3892/etm.2018.6701>.

[289] Zheng C, Xia W, Zhang J. Rock inhibitors in Alzheimer's disease. *Frontiers in Aging*. 2025; 6: 1547883. <https://doi.org/10.3389/fragi.2025.1547883>.

[290] Ye Q, Li X, Gao W, Gao J, Zheng L, Zhang M, *et al.* Role of Rho-associated kinases and their inhibitor fasudil in neurodegenerative diseases. *Frontiers in Neuroscience*. 2024; 18: 1481983. <https://doi.org/10.3389/fnins.2024.1481983>.